US20220211674A1 - Thromboxane Receptor Antagonists in AERD/Asthma - Google Patents
Thromboxane Receptor Antagonists in AERD/Asthma Download PDFInfo
- Publication number
- US20220211674A1 US20220211674A1 US17/705,522 US202217705522A US2022211674A1 US 20220211674 A1 US20220211674 A1 US 20220211674A1 US 202217705522 A US202217705522 A US 202217705522A US 2022211674 A1 US2022211674 A1 US 2022211674A1
- Authority
- US
- United States
- Prior art keywords
- ifetroban
- aspirin
- aerd
- dose
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000006673 asthma Diseases 0.000 title abstract description 31
- 229940044551 receptor antagonist Drugs 0.000 title description 18
- 239000002464 receptor antagonist Substances 0.000 title description 18
- 102000003938 Thromboxane Receptors Human genes 0.000 title description 11
- 108090000300 Thromboxane Receptors Proteins 0.000 title description 11
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 81
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 30
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 claims abstract description 12
- 239000002396 thromboxane receptor blocking agent Substances 0.000 claims abstract description 12
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 claims description 94
- 229950004274 ifetroban Drugs 0.000 claims description 87
- 238000006243 chemical reaction Methods 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 31
- 229940127558 rescue medication Drugs 0.000 claims description 25
- WOHSQDNIXPEQAE-QBKVZTCDSA-M sodium;3-[2-[[(1s,2r,3s,4r)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoate Chemical compound [Na+].CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC([O-])=O)=N1 WOHSQDNIXPEQAE-QBKVZTCDSA-M 0.000 claims description 24
- 238000000586 desensitisation Methods 0.000 claims description 23
- 208000024891 symptom Diseases 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 230000036470 plasma concentration Effects 0.000 claims description 14
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 claims description 7
- 206010008469 Chest discomfort Diseases 0.000 claims description 6
- 208000000592 Nasal Polyps Diseases 0.000 claims description 6
- 206010028735 Nasal congestion Diseases 0.000 claims description 6
- 208000037656 Respiratory Sounds Diseases 0.000 claims description 6
- 206010047924 Wheezing Diseases 0.000 claims description 6
- 206010011224 Cough Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 206010013975 Dyspnoeas Diseases 0.000 claims description 4
- 208000010201 Exanthema Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- 206010028813 Nausea Diseases 0.000 claims description 4
- 206010040744 Sinus headache Diseases 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 230000003187 abdominal effect Effects 0.000 claims description 4
- 208000002173 dizziness Diseases 0.000 claims description 4
- 201000005884 exanthem Diseases 0.000 claims description 4
- 238000011010 flushing procedure Methods 0.000 claims description 4
- 208000013088 frontal headache Diseases 0.000 claims description 4
- 206010025482 malaise Diseases 0.000 claims description 4
- 230000008693 nausea Effects 0.000 claims description 4
- 206010037844 rash Diseases 0.000 claims description 4
- 230000035807 sensation Effects 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 201000005111 ocular hyperemia Diseases 0.000 claims description 3
- 208000038004 exacerbated respiratory disease Diseases 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 description 42
- 229940068196 placebo Drugs 0.000 description 40
- 239000000902 placebo Substances 0.000 description 40
- -1 cysteinyl leukotrienes Chemical class 0.000 description 31
- 150000002148 esters Chemical class 0.000 description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 23
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 description 21
- 230000007423 decrease Effects 0.000 description 17
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 17
- 229940126602 investigational medicinal product Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 11
- 229960005127 montelukast Drugs 0.000 description 11
- 230000000241 respiratory effect Effects 0.000 description 10
- 238000002483 medication Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 7
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 7
- 206010071578 autoimmune retinopathy Diseases 0.000 description 7
- 210000003630 histaminocyte Anatomy 0.000 description 7
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 7
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- DYWAPFDKPAHSED-UHFFFAOYSA-N 2-cycloheptyloxepane Chemical group C1CCCCCC1C1OCCCCC1 DYWAPFDKPAHSED-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 150000004702 methyl esters Chemical class 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 239000008184 oral solid dosage form Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000808 adrenergic beta-agonist Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000008297 liquid dosage form Substances 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- JJBCTCGUOQYZHK-ZSCHJXSPSA-N 2-acetyloxybenzoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.CC(=O)OC1=CC=CC=C1C(O)=O JJBCTCGUOQYZHK-ZSCHJXSPSA-N 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 3
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003434 inspiratory effect Effects 0.000 description 3
- 229940125386 long-acting bronchodilator Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229960004764 zafirlukast Drugs 0.000 description 3
- GQGRDYWMOPRROR-XUSMOFMBSA-N (z)-7-[(1r,2r,3s,5s)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid Chemical compound O([C@H]1C[C@@H]([C@@H]([C@H]1CC\C=C/CCC(O)=O)N1CCCCC1)O)CC(C=C1)=CC=C1C1=CC=CC=C1 GQGRDYWMOPRROR-XUSMOFMBSA-N 0.000 description 2
- IULOBWFWYDMECP-UHFFFAOYSA-N 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethyl]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1CCNS(=O)(=O)C1=CC=C(Cl)C=C1 IULOBWFWYDMECP-UHFFFAOYSA-N 0.000 description 2
- YURNCBVQZBJDAJ-UHFFFAOYSA-N 2-heptenoic acid Chemical compound CCCCC=CC(O)=O YURNCBVQZBJDAJ-UHFFFAOYSA-N 0.000 description 2
- 102000002137 Cysteinyl leukotriene receptor 1 Human genes 0.000 description 2
- 108050009460 Cysteinyl leukotriene receptor 1 Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 2
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000007885 bronchoconstriction Effects 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 229940125369 inhaled corticosteroids Drugs 0.000 description 2
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 2
- 229960001888 ipratropium Drugs 0.000 description 2
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 235000012245 magnesium oxide Nutrition 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000000133 nasal decongestant Substances 0.000 description 2
- 229960000470 omalizumab Drugs 0.000 description 2
- 229940124624 oral corticosteroid Drugs 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003163 prostaglandin D2 derivatives Chemical class 0.000 description 2
- 229940127293 prostanoid Drugs 0.000 description 2
- 206010041232 sneezing Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 2
- 238000013125 spirometry Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003768 thromboxane synthase inhibitor Substances 0.000 description 2
- 229950007952 vapiprost Drugs 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 229960005332 zileuton Drugs 0.000 description 2
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 2
- NIONDZDPPYHYKY-SNAWJCMRSA-N (2E)-hexenoic acid Chemical compound CCC\C=C\C(O)=O NIONDZDPPYHYKY-SNAWJCMRSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- VLMZAUCKMYJSGM-UHFFFAOYSA-N 2-[4-[3-(4-chlorophenyl)sulfonylpropyl]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1CCCS(=O)(=O)C1=CC=C(Cl)C=C1 VLMZAUCKMYJSGM-UHFFFAOYSA-N 0.000 description 1
- JLPYLHLUHJOPNL-UHFFFAOYSA-N 3-[1-[(4-chlorophenyl)methyl]-5-fluoro-3-methyl-2-indolyl]-2,2-dimethylpropanoic acid Chemical compound C12=CC=C(F)C=C2C(C)=C(CC(C)(C)C(O)=O)N1CC1=CC=C(Cl)C=C1 JLPYLHLUHJOPNL-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- UHZXPFSCJFEFPS-UHFFFAOYSA-N 7-(cyclohepten-1-yl)-2,3,4,5-tetrahydrooxepine Chemical class C1CCCCC=C1C1=CCCCCO1 UHZXPFSCJFEFPS-UHFFFAOYSA-N 0.000 description 1
- ZWAVGFSZMACJHA-PMNBYGLBSA-N 7-[2-Trifluoromethyl-4-(2-hydroxyphenyl)-1,3-dioxan-cis-5-yl]-hept-5z-enoic acid Chemical compound OC(=O)CCC\C=C/C[C@@H]1CO[C@H](C(F)(F)F)O[C@@H]1C1=CC=CC=C1O ZWAVGFSZMACJHA-PMNBYGLBSA-N 0.000 description 1
- 208000033309 Analgesic asthma syndrome Diseases 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000980580 Mus musculus Mast cell protease 1 Proteins 0.000 description 1
- 101150058514 PTGES gene Proteins 0.000 description 1
- 101710180319 Protease 1 Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000028347 Sinus disease Diseases 0.000 description 1
- 241001479493 Sousa Species 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- 229940111979 Thromboxane synthase inhibitor Drugs 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940090167 advair Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940053670 asmanex Drugs 0.000 description 1
- 208000024744 aspirin-induced respiratory disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229940087430 biaxin Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CWOWCGMKFUVBRQ-NBGZWUPPSA-L calcium;(z)-7-[(1r,2s,3s,4s)-3-(benzenesulfonamido)-2-bicyclo[2.2.1]heptanyl]hept-5-enoate Chemical compound [Ca+2].N([C@H]1[C@@]2([H])CC[C@](C2)([C@@H]1C\C=C/CCCC([O-])=O)[H])S(=O)(=O)C1=CC=CC=C1.N([C@H]1[C@@]2([H])CC[C@](C2)([C@@H]1C\C=C/CCCC([O-])=O)[H])S(=O)(=O)C1=CC=CC=C1 CWOWCGMKFUVBRQ-NBGZWUPPSA-L 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- YURNCBVQZBJDAJ-WAYWQWQTSA-N cis-2-heptenoic acid Chemical compound CCCC\C=C/C(O)=O YURNCBVQZBJDAJ-WAYWQWQTSA-N 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- PWTCIBWRMQFJBC-ZEMKZVSASA-N domitroban Chemical compound N([C@H]1[C@H]2CC[C@H](C2)[C@@H]1C\C=C/CCCC(=O)O)S(=O)(=O)C1=CC=CC=C1 PWTCIBWRMQFJBC-ZEMKZVSASA-N 0.000 description 1
- 229950010759 domitroban Drugs 0.000 description 1
- 229940103439 dulera Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940085861 flovent Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960000263 levallorphan Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- HUPQYPMULVBQDL-UHFFFAOYSA-N pentanoic acid Chemical compound CCCCC(O)=O.CCCCC(O)=O HUPQYPMULVBQDL-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 229940072266 pulmicort Drugs 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229940014063 qvar Drugs 0.000 description 1
- 229950004496 ramatroban Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- GLLPUTYLZIKEGF-HAVVHWLPSA-N ridogrel Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(=N/OCCCCC(=O)O)\C1=CC=CN=C1 GLLPUTYLZIKEGF-HAVVHWLPSA-N 0.000 description 1
- 229950006674 ridogrel Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940127211 short-acting beta 2 agonist Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940035073 symbicort Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- XUTLOCQNGLJNSA-RGVLZGJSSA-N terbogrel Chemical compound CC(C)(C)\N=C(/NC#N)NC1=CC=CC(C(=C/CCCC(O)=O)\C=2C=NC=CC=2)=C1 XUTLOCQNGLJNSA-RGVLZGJSSA-N 0.000 description 1
- 229950006665 terbogrel Drugs 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
- MWLSOWXNZPKENC-UHFFFAOYSA-N zileuton Chemical compound C1=CC=C2SC(C(N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-UHFFFAOYSA-N 0.000 description 1
- 229940052267 zyflo Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention is related to the use of thromboxane receptor antagonists (e.g., Ifetroban) in the treatment of AERD (aspirin exacerbated respiratory disease) and asthma; and pharmaceutical compositions for the treatment of the same.
- thromboxane receptor antagonists e.g., Ifetroban
- Aspirin Exacerbated Respiratory Disease is a chronic medical condition that consists of asthma, recurrent sinus disease with nasal polyps, as well as a sensitivity to aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). Patients suffering from typically develop reactions triggered by aspirin or other NSAIDs. These reactions include, but are not limited to increased nasal congestion or stuffiness; eye watering or redness; cough, wheezing, or chest tightness; frontal headache or sensation of sinus pain; flushing and/or a rash; nausea and/or abdominal cramping; and a general feeling of malaise, sometimes accompanied by dizziness.
- AERD is characterized by mast cell activation with overproduction of cysteinyl leukotrienes following inhibition of COX-1 by medications like aspirin or NSAIDs.
- the cause of the mast cell activation that occurs following COX-1 inhibition is unknown.
- AERD affects about 10% of adults who have asthma.
- a large proportion (about 40%) of patients who have asthma and nasal polyps are sensitive to aspirin and NSAIDs.
- AERD is also commonly referred to as Samter's Triad or Aspirin Sensitive Asthma.
- Aspirin desensitization may be accomplished, for example, by hospitalizing the patient and instituting a regimen wherein the patient is initially given a very low dose (20-40 mg) of aspirin, with gradual higher doses given every 1.5-3 hours. Following an aspirin-induced reaction (and subsequent stabilization of the patient), further doses of aspirin are administered. The desensitization is considered to be complete once the patient has received a 325 mg dose of aspirin without further reaction. The patient is then discharged and continues treatment with aspirin (typically either 325 mg or 650 mg twice daily). However, aspirin desensitization does not help many AERD patients.
- Other treatments include an antibiotic such as tobramycin or biaxin, a salicylate-free diet, a corticosteroid such as betamethasone, and/or acetylcysteine.
- COX-2 a relatively aspirin-resistant enzyme
- MCs bronchial biopsies from patients with AERD than in those of aspirin tolerant controls.
- PGD2 The capacity of PGD2 to recruit and activate immune effector cells, induce vasodilation, and cause bronchoconstriction would fit well with a role in the pathophysiology of AERD, especially since its production resists suppression by low-dose aspirin.
- Df-treated ptges-/-mice When challenged by inhalation of Lysine aspirin, Df-treated ptges-/-mice exhibited significant increases in airway resistance, accompanied by increases in the levels of cys-LTs, histamine, and mouse MC protease 1 in the BAL fluid.
- the increase in airway resistance was sensitive to interference by zileuton or montelukast (Liu 2013), consistent with the known pharmacology of AERD in humans.
- Exogenous antibody-mediated platelet depletion prior to the Lys-ASA challenge completely eliminated the increases in airway resistance and cys-LTs.
- the present invention is directed in part to providing a method of treating and/or preventing AERD or asthma in human patients by administration of a therapeutically effective amount of a thromboxane receptor antagonist.
- the therapeutically effective amount of thromboxane receptor antagonist is sufficient to provide a plasma concentration of the thromboxane receptor antagonist of about 0.1 ng/ml to about 10,000 ng/ml, preferably from about 1.0 ng/ml to about 6000 ng/ml, or from about 40 ng/ml to about 3500 ng/ml, or from about 300 ng/ml to about 2500 ng/ml.
- the thromoboxane receptor antagonist is a thromboxane A 2 receptor antagonist to a human patient(s).
- the thromboxane A 2 antagonist is [1S-(1 ⁇ ,2 ⁇ ,3 ⁇ ,4 ⁇ )]-2-[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), or pharmaceutically acceptable salts thereof
- the thromboxane A 2 receptor antagonist is ifetroban or a pharmaceutically acceptable salt thereof (e.g., ifetroban sodium) and the dose administered orally to human patients is from about in a daily dose from about 25 mg to about 400 mg.
- the patient(s) will (preferably) require a reduced amount of rescue medications as compared to human patients who are not administered ifetroban.
- the ifetroban is administered orally in an amount from about 150 mg to about 400 mg, from about 200 mg to about 300 mg, and in certain embodiments most preferably about 200 mg.
- the ifetroban is ifetroban sodium.
- the present invention is further directed in part to providing a method for treating and/or preventing AERD or asthma by administration of a therapeutically effective amount of [1S-(1 ⁇ ,2 ⁇ , 3 ⁇ ,4 ⁇ )]-2-[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt (Ifetroban Sodium) to a human patient(s).
- the therapeutically effective amount provides a plasma concentration of the Ifetroban of about 0.1 ng/ml to about 10,000 ng/ml, preferably from about 1.0 ng/ml to about 6000 ng/ml, or from about 40 ng/ml to about 3500 ng/ml, or from about 300 ng/ml to about 2500 ng/ml.
- the thromboxane A 2 receptor antagonist is ifetroban or a pharmaceutically acceptable salt thereof (e.g., ifetroban sodium) and the dose administered orally to human patients is from about in a daily dose from about 25 mg to about 400 mg.
- the patient(s) will (preferably) require a reduced amount of rescue medications as compared to human patients who are not administered ifetroban.
- the ifetroban is administered orally in an amount from about 150 mg to about 400 mg, from about 200 mg to about 300 mg, and in certain embodiments most preferably about 200 mg.
- the ifetroban is ifetroban sodium.
- the present invention provides for methods of preventing, reversing or treating a symptom associated with AERD or asthma including but not limited to nasal congestion (or stuffiness), eye watering, eye redness, coughing, wheezing, chest tightness; frontal headache, sensation of sinus pain, flushing, rash, hives, nausea, abdominal cramping, a general feeling of malaise, dizziness, difficulty breathing, and combinations of any of the foregoing by the administration of a therapeutically effective amount of a thromboxane receptor antagonist (preferably, a thromboxane A 2 receptor antagonist) to a patient in need thereof.
- a thromboxane receptor antagonist preferably, a thromboxane A 2 receptor antagonist
- the therapeutically effective amount of a thromboxane A 2 receptor antagonist provides a plasma concentration of the thromboxane A 2 receptor antagonist of about 0.1 ng/ml to about 10,000 ng/ml, wherein the desired plasma concentration results in the patient experiencing a lessening of said symptom(s).
- the thromboxane A 2 antagonist is [1S-(1 ⁇ ,2 ⁇ ,3 ⁇ ,4 ⁇ )]-2-[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), or pharmaceutically acceptable salts thereof.
- the thromboxane receptor antagonist is [1S-(1 ⁇ ,2 ⁇ , 3 ⁇ ,4 ⁇ )]-2-[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl-benzenepropanoic acid, monosodium salt (Ifetroban Sodium).
- the thromboxane A 2 receptor antagonist is ifetroban or a pharmaceutically acceptable salt thereof (e.g., ifetroban sodium) and the dose administered orally to human patients is from about 150 mg/day to about 400 mg/day, administered in one dose or divided doses.
- the thromboxane A 2 receptor antagonist is ifetroban sodium and the dose is about 200 mg/day when administered orally to a human patient(s) suffering from AERD and/or asthma.
- the invention is also directed in part to a method of reducing rescue medications as a result of an aspirin-induced reaction in a human patient(s) suffering from AERD, comprising administering ifetroban or a pharmaceutically acceptable salt thereof in a daily dose from about 25 mg to about 400 mg.
- the patient(s) will (preferably) require a reduced amount of rescue medications as compared to human patients who are not administered ifetroban.
- the ifetroban is administered orally in an amount from about 150 mg to about 400 mg, from about 200 mg to about 300 mg, and in certain embodiments most preferably about 200 mg.
- the ifetroban is ifetroban sodium.
- the invention is also directed in part to a method of reducing the symptoms of aspirin desensitization in a human AERD patient(s), comprising rescue medications as a result of an aspirin-induced reaction in a human patient(s) suffering from AERD, comprising orally administering ifetroban or a pharmaceutically acceptable salt thereof in a daily dose from about 25 mg to about 400 mg.
- the patient(s) will (preferably) require a reduced amount of rescue medications as compared to human patients who are not administered ifetroban.
- the ifetroban is administered orally in an amount from about 150 mg to about 400 mg, from about 200 mg to about 300 mg, and in certain embodiments most preferably about 200 mg.
- the ifetroban is ifetroban sodium.
- the thromboxane A 2 receptor antagonist may be ifetroban or a pharmaceutically acceptable salt thereof (e.g., ifetroban sodium) in a daily dose of about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, and about 400 mg.
- the daily dose may be administered once daily, twice daily, three times daily, or four times daily.
- terapéuticaally effective amount refers to that amount of a substance that produces some desired local or systemic effect at a reasonable benefit/risk ratio applicable to any treatment.
- the effective amount of such substance will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- thromboxane A 2 receptor antagonist refers to a compound that inhibits the expression or activity of a thromboxane receptor by at least or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% in a standard bioassay or in vivo or when used in a therapeutically effective dose.
- a thromboxane A 2 receptor antagonist inhibits binding of thromboxane A 2 to the receptor.
- Thromboxane A 2 receptor antagonists include competitive antagonists (i.e., antagonists that compete with an agonist for the receptor) and non-competitive antagonists.
- Thromboxane A 2 receptor antagonists include antibodies to the receptor. The antibodies may be monoclonal. They may be human or humanized antibodies.
- Thromboxane A 2 receptor antagonists also include thromboxane synthase inhibitors, as well as compounds that have both thromboxane A 2 receptor antagonist activity and thromboxane synthase inhibitor activity.
- FIG. 1 depicts the deletion or blockade of TP receptors attenuates aspirin sensitivity in PGE2-deficient mice.
- A Peak change in RL occurring in response to Lys-ASA challenge of ptges-/- or ptges/tpr-/-(DKO) mice 24 h after their final treatment with PBS or Df.
- B Peak change in RL in ptges-/-mice receiving two doses of the TP receptor selective antagonist SQ29.548 prior to challenge with Lys-ASA.
- C Levels of cys-LTs, mMCP-1, and histamine in BAL fluids from the same mice as in (B). Results are from 10 mice/group. (Adapted from Liu 2013).
- thromboxane A 2 receptor antagonists have been an objective of many pharmaceutical companies for approximately 30 years (see, Dogne J-M, et al., Exp. Opin. Ther. Patents 11: 1663-1675 (2001)).
- Certain individual compounds identified by these companies, either with or without concomitant thromboxane A 2 synthase inhibitory activity, include ifetroban (BMS), ridogrel (Janssen), terbogrel (BI), UK-147535 (Pfizer), GR 32191 (Glaxo), and S-18886 (Servier).
- BMS ifetroban
- ridogrel Jikker
- BI terbogrel
- UK-147535 Pfizer
- GR 32191 Gaxo
- S-18886 Servier
- These compounds also prevent vasoconstriction induced by thromboxane A 2 and other prostanoids that act on the thromboxane A 2 receptor within the vascular bed, and thus may be beneficial for use in preventing and/or treating hepatorenal syndrome and/or hepatic encephalopathy.
- Suitable thromboxane A 2 receptor antagonists for use in the present invention may include, for example, but are not limited to small molecules such as ifetroban (BMS; [1S-(1 ⁇ ,2 ⁇ ,3 ⁇ ,4 ⁇ )]-2-[3-[4-[(pentylamino)carbony-1]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2 yl]methyl]benzenepropanoic acid), as well as others described in U.S. Patent Application Publication No. 2009/0012115, the disclosure of which is hereby incorporated by reference in its entirety.
- BMS ifetroban
- Additional thromboxane A 2 receptor antagonists suitable for use herein are also described in U.S. Pat. No. 4,839,384 (Ogletree); U.S. Pat. No. 5,066,480 (Ogletree, et al.); 5,100,889 (Misra, et al.); 5,312,818 (Rubin, et al.); 5,399,725 (Poss, et al.); and 6,509,348 (Ogletree), the disclosures of which are hereby incorporated by reference in their entireties. These may include, but are not limited to, interphenylene 7-oxabicyclo-heptyl substituted heterocyclic amide prostaglandin analogs as disclosed in U.S. Pat. No. 5,100,889, including:
- thromboxane A 2 receptor antagonists suitable for use herein include, but are not limited to vapiprost (which is a preferred example), (E)-5-[[(pyridinyl)]3-(trifluoromethyl)phenyl]methylene]amino]-oxy]pentanoic acid also referred to as R68,070-Janssen Research Laboratories, 3-[1-(4-chlorophenylmethyl)-5-fluoro-3-methylindol-2-yl]-2,-2-dimethylpropanoic acid [(L-655240 Merck-Frosst) Eur. J. Pharmacol. 135(2):193, Mar.
- the preferred thromboxane A 2 receptor antagonist of the present invention is ifetroban or any pharmaceutically acceptable salts thereof.
- the preferred thromboxane A 2 receptor antagonist is ifetroban sodium (known chemically as [1S-(1 ⁇ ,2 ⁇ ,3 ⁇ ,4 ⁇ )]-2-[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt.
- the AERD and/or asthma is treated via the administration of a thromboxane receptor antagonist (e.g., a thromboxane A 2 receptor antagonist) ranging from about 0.1 ng/ml to about 10,000 ng/ml.
- a thromboxane receptor antagonist e.g., a thromboxane A 2 receptor antagonist
- the plasma concentration of thromboxane receptor antagonist ranges from about 1 ng/ml to about 1,000 ng/ml, preferably from about 1.0 ng/ml to about 6000 ng/ml, or from about 40 ng/ml to about 3500 ng/ml, or from about 300 ng/ml to about 2500 ng/ml.
- the thromboxane A 2 receptor antagonist is ifetroban or a pharmaceutically acceptable salt thereof (e.g., ifetroban sodium) and the dose administered orally to human patients is from about 150 mg/day to about 400 mg/day, administered in one dose or divided doses. In certain preferred embodiments, the thromboxane A 2 receptor antagonist is ifetroban sodium and the dose is about 200 mg/day when administered orally to a human patient(s) suffering from AERD and/or asthma.
- a pharmaceutically acceptable salt thereof e.g., ifetroban sodium
- the desired plasma concentration for providing a therapeutic effect for the treatment of AERD and/or asthma should be greater than about 10 ng/mL (ifetroban free acid).
- Some therapeutic effect of thromboxane A 2 receptor antagonist, e.g., ifetroban, may be seen at concentrations of greater than about 1 ng/mL.
- the dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.
- daily doses of the thromboxane A 2 receptor antagonists ranging from about 0.1 mg to about 5000 mg should be administered.
- the daily dose of thromboxane A 2 receptor antagonists ranges from about 1 mg to about 1000 mg; about 10 mg to about 1000 mg; about 50 mg to about 500 mg; about 100 mg to about 500 mg; about 200 mg to about 500 mg; about 300 mg to about 500 mg; and about 400 mg to about 500 mg per day.
- a daily dose of ifetroban sodium from about 10 mg to about 250 mg will produce effective plasma levels of ifetroban free acid.
- the thromboxane A 2 receptor antagonists of the present invention may be administered by any pharmaceutically effective route.
- the thromboxane A 2 receptor antagonists may be formulated in a manner such that they can be administered orally, intranasally, rectally, vaginally, sublingually, buccally, parenterally, or transdermally, and, thus, be formulated accordingly.
- the thromboxane A 2 receptor antagonists may be formulated in a pharmaceutically acceptable oral dosage form.
- Oral dosage forms may include, but are not limited to, oral solid dosage forms and oral liquid dosage forms.
- Oral solid dosage forms may include, but are not limited to, tablets, capsules, caplets, powders, pellets, multiparticulates, beads, spheres and any combinations thereof. These oral solid dosage forms may be formulated as immediate release, controlled release, sustained (extended) release or modified release formulations.
- the oral solid dosage forms of the present invention may also contain pharmaceutically acceptable excipients such as fillers, diluents, lubricants, surfactants, glidants, binders, dispersing agents, suspending agents, disintegrants, viscosity-increasing agents, film-forming agents, granulation aid, flavoring agents, sweetener, coating agents, solubilizing agents, and combinations thereof
- pharmaceutically acceptable excipients such as fillers, diluents, lubricants, surfactants, glidants, binders, dispersing agents, suspending agents, disintegrants, viscosity-increasing agents, film-forming agents, granulation aid, flavoring agents, sweetener, coating agents, solubilizing agents, and combinations thereof
- the oral solid dosage forms of the present invention may contain a suitable amount of controlled-release agents, extended-release agents, modified-release agents.
- Oral liquid dosage forms include, but are not limited to, solutions, emulsions, suspensions, and syrups. These oral liquid dosage forms may be formulated with any pharmaceutically acceptable excipient known to those of skill in the art for the preparation of liquid dosage forms. For example, water, glycerin, simple syrup, alcohol and combinations thereof.
- the thromboxane A 2 receptor antagonists may be formulated into a dosage form suitable for parenteral use.
- the dosage form may be a lyophilized powder, a solution, suspension (e.g., depot suspension).
- the thromboxane receptor antagonists may be formulated into a topical dosage form such as, but not limited to, a patch, a gel, a paste, a cream, an emulsion, liniment, balm, lotion, and ointment.
- a significant proportion of patients that suffer from asthma take one or more medications on a daily (chronic) basis in order to prevent or attenuate symptoms of asthma.
- Such drugs include corticosteroids (including but not limited to inhaled corticosteroids), Cromolyn, Omalizumab, short or long-acting beta-2 agonists (typically inhaled), leukotriene modifiers (e.g., zafirlukast (Accolate®), montelukast (Singulair®), and zileuton (Zyflo®)), and theophylline.
- Advair a combination drug that includes a steroid and a long-acting bronchodilator drug.
- Inhaled steroid medications include but are not limited to the following: Aerobid®, Asmanex®, Azmacort®, Dulera® (a combination drug that also includes a long-acting bronchodilator drug), Flovent®, Pulmicort®, Symbicort® (a combination drug that includes a steroid and a long-acting bronchodilator drug), Qvar®, and the like.
- Inhaled steroids come in three forms: the metered dose inhaler (MDI), dry powder inhaler (DPI), and nebulizer solutions.
- Omalizumab (trade name Xolair®, Roche/Genentech and Novartis) is a humanized antibody originally designed to reduce sensitivity to inhaled or ingested allergens, especially in the control of moderate to severe allergic asthma, which does not respond to high doses of corticosteroids.
- the present method of treatment further contemplates combination therapy comprising administering a thromboxane receptor antagonist and one or more of the above drugs to a human patient suffering from AERD and/or asthma.
- ifetroban sodium tablets are prepared with the following ingredients listed in Table 1:
- the sodium salt of ifetroban, magnesium oxide, mannitol, microcrystalline cellulose, and crospovidone is mixed together for about 2 to about 10 minutes employing a suitable mixer.
- the resulting mixture is passed through a #12 to #40 mesh size screen. Thereafter, magnesium stearate and colloidal silica are added and mixing is continued for about 1 to about 3 minutes.
- the resulting homogeneous mixture is then compressed into tablets each containing 35 mg, ifetroban sodium salt.
- the sodium salt of ifetroban, preservatives and sodium chloride are dissolved in 3 liters of water for injection and then the volume is brought up to 5 liters.
- the solution is filtered through a sterile filter and aseptically filled into pre-sterilized vials which are then closed with pre-sterilized rubber closures.
- Each vial contains a concentration of 75 mg of active ingredient per 150 ml of solution.
- Example IV is a multicenter, double-blind, randomized, placebo-controlled trial to determine the safety of oral ifetroban in patients with a history of aspirin exacerbated respiratory disease (AERD).
- AERD aspirin exacerbated respiratory disease
- the eligible subjects were randomized (3:1 active to placebo) in this 7-day study which consisted of a screening, treatment and follow-up period. Any subject receiving at least a partial dose of IMP were not replaced and included in the study analysis. Of 19 subjects enrolled and randomized to study treatment, 14 (74%) were randomized to the ifetroban group and 5 (26%) to the placebo group. Of those 14 randomized to ifetroban, 12 (86%) subjects were treated and 100% of those treated completed treatment. Of 5 subjects randomized to placebo, 4 (80%) started treatment and 100% completed treatment. All treated subjects were analyzed for safety and efficacy variables.
- a placebo treatment arm was included in this study to provide data on the spontaneous response rate of AERD subjects, as well as to help identify any safety or efficacy signals in the subjects receiving ifetroban.
- subjects with asthma assigned to placebo have demonstrated improvement in symptoms, quality of life, and even in lung function, such as FEV1.
- the placebo effect in asthma can be as great as 30 to 50% depending on which endpoint is chosen (Castro, 2007 ; Placebo versus Best - Available - Therapy Control Group in Clinical Trials for Pharmacologic Therapies. Proceedings of the American Thoracic Society, 570-573).
- montelukast substantially increases the safety of aspirin challenge/desensitization and it is the standard of care to use montelukast as a pre-treatment for subjects with AERD undergoing a planned aspirin challenge/desensitization. Because montelukast does not inhibit CYP2C9 or CYP3A4, montelukast was not expected to affect the elimination of ifetroban.
- the primary objective of this study was to determine the safety of oral ifetroban compared to placebo as measured by a ⁇ 20% decrease in Forced Expiratory Volume in 1 second (FEV1) compared to baseline following a dose of Investigational Medicinal Product (IMP) (Study Day 1) or following a dose of IMP but prior to initiation of the aspirin challenge.
- FEV1 Forced Expiratory Volume in 1 second
- Secondary objectives were: (i) to determine the safety of oral ifetroban compared to placebo as measured by peak Nasal Inspiratory Flow Rate (NIFR) compared to baseline following a dose of IMP (Study Day 1) or following a dose of IMP but prior to initiation of the aspirin challenge; (ii) to determine the safety of oral ifetroban compared to placebo as measured by the change in Total Nasal Symptom Score (TNSS) compared to baseline following a dose of IMP (Study Day 1) or following a dose of IMP but prior to initiation of the aspirin challenge; (iii) to determine the safety and tolerability of oral ifetroban compared to placebo as measured by treatment-emergent adverse events; (iv) to determine the efficacy of oral ifetroban compared to placebo in decreasing the respiratory reaction to oral aspirin as measured by the change in FEV1 compared to baseline during the aspirin challenge; (v) to determine the efficacy of oral ifetroban compared to placebo in decreasing the respiratory reaction
- the main criteria for inclusion in the study were adults with a history of physician-diagnosed stable asthma (FEV1 of at least 1.25 Liters (L) and 60% or better than predicted (calculated by spirometer based on gender, age, etc.) on two previous visits with no more than a 10% variation in those values, no increase in baseline dose of oral glucocorticoids for asthma for at least three months, and no history of hospitalization or emergency room visits for asthma for at least the prior six months), who have a history of nasal polyposis and have a history of at least one clinical reaction to oral aspirin or other nonselective cyclooxygenase (COX) inhibitor with features of lower (cough, chest tightness, wheezing, dyspnea) and/or upper (rhinorrhea, sneezing, nasal obstruction, conjunctival itching and discharge) airway involvement, and who are currently receiving montelukast (at least 10 mg per day, oral) or zafirlukast (
- Subjects were allowed to enter the trial on the following medications: oral corticosteroids at a dose of ⁇ 10 mg/day prednisone or prednisone equivalent, inhaled/nasal corticosteroids, inhaled long-acting ⁇ -adrenergic agonists and inhaled ipratropium; however, no modifications were allowed during the study except for a temporary increase in the dose of oral corticosteroids if asthma worsened requiring such intervention. Subjects were required to stop using short-acting ⁇ -adrenergic agonists 24 hours prior, nasal decongestants and antihistamines 48 hours prior to first dose of IMP and throughout the study unless asthma worsened requiring such intervention.
- nasal, inhaled corticosteroids and inhaled long acting beta-adrenergic agonists and inhaled ipratropium were allowed to be used during the study without modification to the subject's dosing regimen if the subject entered the trial on such medications. It is believed that these medications would not mask a potential response to the aspirin challenge.
- Inhaled short acting beta-adrenergic agonists, nasal decongestants, and antihistamines were not allowed for specified periods prior to the study and through the initiation of the aspirin challenge as these medications may mask a potential response and thus affect the study efficacy endpoints. Warfarin, antiplatelet, or anticoagulant medications were prohibited 2 weeks prior to enrollment and during the course of the study.
- the primary efficacy variable assessed was FEV1 measured by spirometry.
- Secondary efficacy variables included the NIFR using a Youlten meter (or similar), and the subject-completed questionnaire, Total Nasal Symptom Score (TNSS). Additional efficacy variables were the incidence of asthmatic reactions, the incidence of respiratory reactions to oral aspirin, the amount of medications used to manage an aspirin-induced reaction and the aspirin dose at which a reaction was provoked during the desensitization process.
- the treatment period consisted of a phase A assessing safety and efficacy of IMP administered Day 1 and Day 2 followed by a phase B assessing safety and efficacy of IMP during the aspirin challenge on Day 2 and Day 3. Subjects experiencing a decrease in FEV1 of ⁇ 20% during phase A would not continue to phase B of the study.
- the follow-up period started upon completion of the aspirin challenge and ended on Day 7 with a phone call to assess for safety. All subjects were required to be taking either oral montelukast or zafirlukast (at least 10 mg/day or 20 mg twice per day, respectively) one week prior to the study and for the duration of the study.
- Ifetroban was supplied as 50-mg ifetroban sodium capsules and orally administered at a dose of 200 mg every 24 hours for three consecutive days. Identically appearing placebo capsules were provided for blinding purposes and 4 capsules administered orally every 24 hours for 3 consecutive days. The duration of IMP treatment was 3 days. The study duration was 7 days.
- phase B No subject met this primary endpoint therefore all subjects continued to phase B of the study.
- FEV1 was comparable between treatment groups (Table 8 and Table 10). Mean changes from baseline FEV1 remained well below 20% throughout the treatment period in both treatment groups. No clear trends were observed between treatment groups.
- FEV1 was comparable between treatment groups. Mean changes from baseline FEV1 remained well below 20% throughout the treatment period in both treatment groups. No clear trends were observed between treatment groups.
- NIFR peak inspiratory flow rate
- TNSS total nasal symptom score
- the incidence of the AIR provoked at each aspirin dose was evaluated between treatment groups and summarized in Table 6. All subjects who experienced an AIR reacted to a provoking dose of 60 and/or 100 mg. No reaction occurred after the 100-mg provoking dose. All initial reactions in the placebo arm occurred at the 60-mg dose while in the ifetroban arm, 50% of the initial reactions occurred at 60-mg and the other half at 100-mg. One subject on placebo experienced a provoking dose reaction at 60 mg on Day 2 and another AIR on Day 3 at 100 mg. The severity of the 2 AIRs were comparable to one another. All other subjects experienced a single AIR during the aspirin desensitization process.
- the severity of the AIRs were compared between treatment groups by the number of separate symptoms that manifested during the aspirin challenge. The total number of symptoms are based on 14 AIRs that occurred in 13 subjects, 10 ifetroban-treated subjects and 3 placebo-treated subjects. As mentioned previously, 1 subject on the placebo arm experienced 2 AIRs. The average number of symptoms per AIR was comparable between treatment groups. Both arms experienced a bronchial reaction ( ⁇ 20% decrease in FEV1, wheezing, chest tightness) as part of the AIR at a similar rate. While an upper respiratory effect (rhinorrhea, nasal obstruction, sneezing) was equally as common between treatment groups, an ocular manifestation seems to trend toward the placebo arm more often than on the ifetroban arm. AIR severity in the study is reported in Table 7 below.
- the primary endpoint was not met; ifetroban did not cause a ⁇ 20% decrease in FEV1 during the course of IMP treatment or the aspirin desensitization process. Mean changes from baseline FEV1 remained well below 20% throughout the treatment period in both groups with no clear trends observed. While no appreciable difference was observed in the proportion of subjects with worsening NIFR or TNSS between treatment groups, there is an observed trend in favor of the ifetroban group toward greater improvements to NIFR and TNSS during phase A and phase B. Moreover, there is an apparent trend toward fewer rescue medications in favor of the ifetroban group and, while an upper respiratory effect was equally as common between treatment groups, an ocular manifestation seems to trend toward the placebo arm more often than on the ifetroban arm.
Abstract
Description
- The present invention is related to the use of thromboxane receptor antagonists (e.g., Ifetroban) in the treatment of AERD (aspirin exacerbated respiratory disease) and asthma; and pharmaceutical compositions for the treatment of the same.
- Aspirin Exacerbated Respiratory Disease (AERD) is a chronic medical condition that consists of asthma, recurrent sinus disease with nasal polyps, as well as a sensitivity to aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). Patients suffering from typically develop reactions triggered by aspirin or other NSAIDs. These reactions include, but are not limited to increased nasal congestion or stuffiness; eye watering or redness; cough, wheezing, or chest tightness; frontal headache or sensation of sinus pain; flushing and/or a rash; nausea and/or abdominal cramping; and a general feeling of malaise, sometimes accompanied by dizziness.
- From a scientific perspective, AERD is characterized by mast cell activation with overproduction of cysteinyl leukotrienes following inhibition of COX-1 by medications like aspirin or NSAIDs. The cause of the mast cell activation that occurs following COX-1 inhibition is unknown.
- AERD affects about 10% of adults who have asthma. A large proportion (about 40%) of patients who have asthma and nasal polyps are sensitive to aspirin and NSAIDs.
- It is typical that human patients who are suffering from AERD also have asthma, nasal congestion, and nasal polyps. Such patients often do not respond to conventional treatments.
- AERD is also commonly referred to as Samter's Triad or Aspirin Sensitive Asthma.
- The most common treatment currently available for AERD is aspirin desensitization. Aspirin desensitization may be accomplished, for example, by hospitalizing the patient and instituting a regimen wherein the patient is initially given a very low dose (20-40 mg) of aspirin, with gradual higher doses given every 1.5-3 hours. Following an aspirin-induced reaction (and subsequent stabilization of the patient), further doses of aspirin are administered. The desensitization is considered to be complete once the patient has received a 325 mg dose of aspirin without further reaction. The patient is then discharged and continues treatment with aspirin (typically either 325 mg or 650 mg twice daily). However, aspirin desensitization does not help many AERD patients.
- Other treatments include an antibiotic such as tobramycin or biaxin, a salicylate-free diet, a corticosteroid such as betamethasone, and/or acetylcysteine.
- Aspirin challenge of subjects with aspirin exacerbated respiratory disease (AERD) results in the activation of mast cells (MCs), as evidenced by increases in the levels of tryptase in both serum (Bochenek 2003) and nasal lavage fluid (Fischer 1994). In addition, the levels of 9α-11β-PGF2, a PGD2 metabolite, increase in the plasma during the reaction to aspirin (Bochenek 2003). PGD2 has been shown to activate the thromboxane prostanoid (TP) receptors found on bronchial smooth muscle thereby causing bronchoconstriction (Armour 1989; Bochenek 2003; Pettipher 2007). Administration of ifetroban in vitro has been shown to inhibit contraction of guinea pig trachea elicited by PGD2 (Ogletree 1992) and to both preempt and reverse TP receptor-induced bronchospasm in rats and guinea pigs. Direct endobronchial application of lysine-aspirin does not decrease the levels of PGD2 and PGD2 metabolites recovered from bronchoalveolar lavage (BAL) fluids from AERD patients. However, endobronchial application of lysine-aspirin does reduce the concentration of other prostaglandins (Sladek 1994; Szczeklik 1996). Thus, PGD2 production in AERD resists suppression by aspirin.
- The expression of COX-2, a relatively aspirin-resistant enzyme, is expressed by a larger percentage of MCs in bronchial biopsies from patients with AERD than in those of aspirin tolerant controls (Sousa 1997). Since global expression of COX-2 in nasal polyps is reduced in AERD relative to aspirin-tolerant controls (Picado 1999), the selective upregulation of COX-2 expression by MCs likely reflects cell-specific differences in the regulation of the COX-2 isoform. Thus, the capacity for MCs to release PGD2 in AERD during aspirin challenge may be due to their preferential utilization of COX-2 for this function. The capacity of PGD2 to recruit and activate immune effector cells, induce vasodilation, and cause bronchoconstriction would fit well with a role in the pathophysiology of AERD, especially since its production resists suppression by low-dose aspirin.
- Human studies demonstrate markedly impaired COX-2-dependent synthesis of PGE2 in the sinonasal tissues of patients with AERD compared with aspirin-tolerant controls (Picado 1999; Yoshimura 2008). Previous clinical studies also strongly support a critical role of platelet-adherent granulocytes as a source of cysteinyl leukotrienes (cys-LTs) in human subjects with AERD (Laidlaw 2012). To further explore the pathogenetic consequences of a deficit in COX-2-dependent PGE2 generation, sustained PGD2 generation, and the role of platelets in AERD, mice lacking microsomal PGE2 synthase (ptges-/-mice) were developed (Liu 2012; Liu 2013). PGE2 synthase is the dominant terminal enzyme responsible for conversion of COX-2-derived PGH2 to PGE2 (Murakami 2000).
- To elicit the AERD phenotype in the ptges-/-mice, six doses of an extract of allergens from the house dust mite Dermatophagoides farina (Df) were administered and the animals developed marked eosinophilic bronchovascular inflammation compared with WT controls (Liu 2012). The blood and lungs of ptges-/-mice contained markedly increased numbers of platelets adhering to granulocytes, similar to the findings in humans. When challenged by inhalation of Lysine aspirin, Df-treated ptges-/-mice exhibited significant increases in airway resistance, accompanied by increases in the levels of cys-LTs, histamine, and
mouse MC protease 1 in the BAL fluid. The increase in airway resistance was sensitive to interference by zileuton or montelukast (Liu 2013), consistent with the known pharmacology of AERD in humans. Exogenous antibody-mediated platelet depletion prior to the Lys-ASA challenge completely eliminated the increases in airway resistance and cys-LTs. Moreover, deletion of TP receptors from ptges-/-mice or the administration of SQ29,548, a selective antagonist of the TP receptor, completely blocked the reaction to aspirin and the rise in cys-LTs (FIG. 1 ). These findings imply that signaling through TP receptors is critical for platelets to mediate the transcellular synthesis of leukotriene C4 (LTC4) during challenge with aspirin. These observations support the hypothesis that TP receptor blockade will reduce the synthesis of cys-LTs in AERD and thereby provide a new treatment modality for the disease and ease the desensitization to aspirin. - It is an object of the present invention to provide new methods of treating AERD and/or asthma.
- It is an object of the invention to reduce rescue medications needed as a result of an aspirin-induced reaction in a human patient suffering from AERD.
- It is another object of the invention to reduce the symptoms of aspirin desensitization in AERD patients.
- It accordance with the above object and others, the present invention is directed in part to providing a method of treating and/or preventing AERD or asthma in human patients by administration of a therapeutically effective amount of a thromboxane receptor antagonist. Preferably, the therapeutically effective amount of thromboxane receptor antagonist is sufficient to provide a plasma concentration of the thromboxane receptor antagonist of about 0.1 ng/ml to about 10,000 ng/ml, preferably from about 1.0 ng/ml to about 6000 ng/ml, or from about 40 ng/ml to about 3500 ng/ml, or from about 300 ng/ml to about 2500 ng/ml.
- In certain embodiments, the thromoboxane receptor antagonist is a thromboxane A2 receptor antagonist to a human patient(s). In preferred embodiments, the thromboxane A2 antagonist is [1S-(1α,2α,3α,4α)]-2-[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), or pharmaceutically acceptable salts thereof In certain preferred embodiments, the thromboxane A2 receptor antagonist is ifetroban or a pharmaceutically acceptable salt thereof (e.g., ifetroban sodium) and the dose administered orally to human patients is from about in a daily dose from about 25 mg to about 400 mg. In such embodiments, the patient(s) will (preferably) require a reduced amount of rescue medications as compared to human patients who are not administered ifetroban. In certain preferred embodiments, the ifetroban is administered orally in an amount from about 150 mg to about 400 mg, from about 200 mg to about 300 mg, and in certain embodiments most preferably about 200 mg. In certain preferred embodiments, the ifetroban is ifetroban sodium.
- The present invention is further directed in part to providing a method for treating and/or preventing AERD or asthma by administration of a therapeutically effective amount of [1S-(1α,2α, 3α,4α)]-2-[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt (Ifetroban Sodium) to a human patient(s). Preferably, the therapeutically effective amount provides a plasma concentration of the Ifetroban of about 0.1 ng/ml to about 10,000 ng/ml, preferably from about 1.0 ng/ml to about 6000 ng/ml, or from about 40 ng/ml to about 3500 ng/ml, or from about 300 ng/ml to about 2500 ng/ml. In certain preferred embodiments, the thromboxane A2 receptor antagonist is ifetroban or a pharmaceutically acceptable salt thereof (e.g., ifetroban sodium) and the dose administered orally to human patients is from about in a daily dose from about 25 mg to about 400 mg. In such embodiments, the patient(s) will (preferably) require a reduced amount of rescue medications as compared to human patients who are not administered ifetroban. In certain preferred embodiments, the ifetroban is administered orally in an amount from about 150 mg to about 400 mg, from about 200 mg to about 300 mg, and in certain embodiments most preferably about 200 mg. In certain preferred embodiments, the ifetroban is ifetroban sodium.
- In accordance with the above objects, the present invention provides for methods of preventing, reversing or treating a symptom associated with AERD or asthma including but not limited to nasal congestion (or stuffiness), eye watering, eye redness, coughing, wheezing, chest tightness; frontal headache, sensation of sinus pain, flushing, rash, hives, nausea, abdominal cramping, a general feeling of malaise, dizziness, difficulty breathing, and combinations of any of the foregoing by the administration of a therapeutically effective amount of a thromboxane receptor antagonist (preferably, a thromboxane A2 receptor antagonist) to a patient in need thereof. In certain preferred embodiments, the therapeutically effective amount of a thromboxane A2 receptor antagonist provides a plasma concentration of the thromboxane A2 receptor antagonist of about 0.1 ng/ml to about 10,000 ng/ml, wherein the desired plasma concentration results in the patient experiencing a lessening of said symptom(s). In preferred embodiments, the thromboxane A2 antagonist is [1S-(1α,2α,3α,4α)]-2-[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), or pharmaceutically acceptable salts thereof. In another preferred embodiment, the thromboxane receptor antagonist is [1S-(1α,2α, 3α,4α)]-2-[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl-benzenepropanoic acid, monosodium salt (Ifetroban Sodium). In certain preferred embodiments, the thromboxane A2 receptor antagonist is ifetroban or a pharmaceutically acceptable salt thereof (e.g., ifetroban sodium) and the dose administered orally to human patients is from about 150 mg/day to about 400 mg/day, administered in one dose or divided doses. In certain preferred embodiments, the thromboxane A2 receptor antagonist is ifetroban sodium and the dose is about 200 mg/day when administered orally to a human patient(s) suffering from AERD and/or asthma.
- The invention is also directed in part to a method of reducing rescue medications as a result of an aspirin-induced reaction in a human patient(s) suffering from AERD, comprising administering ifetroban or a pharmaceutically acceptable salt thereof in a daily dose from about 25 mg to about 400 mg. In such embodiments, the patient(s) will (preferably) require a reduced amount of rescue medications as compared to human patients who are not administered ifetroban. In certain preferred embodiments, the ifetroban is administered orally in an amount from about 150 mg to about 400 mg, from about 200 mg to about 300 mg, and in certain embodiments most preferably about 200 mg. In certain preferred embodiments, the ifetroban is ifetroban sodium.
- The invention is also directed in part to a method of reducing the symptoms of aspirin desensitization in a human AERD patient(s), comprising rescue medications as a result of an aspirin-induced reaction in a human patient(s) suffering from AERD, comprising orally administering ifetroban or a pharmaceutically acceptable salt thereof in a daily dose from about 25 mg to about 400 mg. In such embodiments, the patient(s) will (preferably) require a reduced amount of rescue medications as compared to human patients who are not administered ifetroban. In certain preferred embodiments, the ifetroban is administered orally in an amount from about 150 mg to about 400 mg, from about 200 mg to about 300 mg, and in certain embodiments most preferably about 200 mg. In certain preferred embodiments, the ifetroban is ifetroban sodium.
- In any of the above methods, the thromboxane A2 receptor antagonist may be ifetroban or a pharmaceutically acceptable salt thereof (e.g., ifetroban sodium) in a daily dose of about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, and about 400 mg. The daily dose may be administered once daily, twice daily, three times daily, or four times daily.
- The phrase “therapeutically effective amount” refers to that amount of a substance that produces some desired local or systemic effect at a reasonable benefit/risk ratio applicable to any treatment. The effective amount of such substance will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- The term “thromboxane A2 receptor antagonist” as used herein refers to a compound that inhibits the expression or activity of a thromboxane receptor by at least or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% in a standard bioassay or in vivo or when used in a therapeutically effective dose. In certain embodiments, a thromboxane A2 receptor antagonist inhibits binding of thromboxane A2 to the receptor. Thromboxane A2 receptor antagonists include competitive antagonists (i.e., antagonists that compete with an agonist for the receptor) and non-competitive antagonists. Thromboxane A2 receptor antagonists include antibodies to the receptor. The antibodies may be monoclonal. They may be human or humanized antibodies. Thromboxane A2 receptor antagonists also include thromboxane synthase inhibitors, as well as compounds that have both thromboxane A2 receptor antagonist activity and thromboxane synthase inhibitor activity.
-
FIG. 1 depicts the deletion or blockade of TP receptors attenuates aspirin sensitivity in PGE2-deficient mice. (A) Peak change in RL occurring in response to Lys-ASA challenge of ptges-/- or ptges/tpr-/-(DKO) mice 24 h after their final treatment with PBS or Df. (B) Peak change in RL in ptges-/-mice receiving two doses of the TP receptor selective antagonist SQ29.548 prior to challenge with Lys-ASA. (C) Levels of cys-LTs, mMCP-1, and histamine in BAL fluids from the same mice as in (B). Results are from 10 mice/group. (Adapted from Liu 2013). - The discovery and development of thromboxane A2 receptor antagonists has been an objective of many pharmaceutical companies for approximately 30 years (see, Dogne J-M, et al., Exp. Opin. Ther. Patents 11: 1663-1675 (2001)). Certain individual compounds identified by these companies, either with or without concomitant thromboxane A2 synthase inhibitory activity, include ifetroban (BMS), ridogrel (Janssen), terbogrel (BI), UK-147535 (Pfizer), GR 32191 (Glaxo), and S-18886 (Servier). Preclinical pharmacology has established that this class of compounds has effective antithrombotic activity obtained by inhibition of the thromboxane pathway. These compounds also prevent vasoconstriction induced by thromboxane A2 and other prostanoids that act on the thromboxane A2 receptor within the vascular bed, and thus may be beneficial for use in preventing and/or treating hepatorenal syndrome and/or hepatic encephalopathy.
- Suitable thromboxane A2 receptor antagonists for use in the present invention may include, for example, but are not limited to small molecules such as ifetroban (BMS; [1S-(1α,2α,3α,4α)]-2-[3-[4-[(pentylamino)carbony-1]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2 yl]methyl]benzenepropanoic acid), as well as others described in U.S. Patent Application Publication No. 2009/0012115, the disclosure of which is hereby incorporated by reference in its entirety.
- Additional thromboxane A2 receptor antagonists suitable for use herein are also described in U.S. Pat. No. 4,839,384 (Ogletree); U.S. Pat. No. 5,066,480 (Ogletree, et al.); 5,100,889 (Misra, et al.); 5,312,818 (Rubin, et al.); 5,399,725 (Poss, et al.); and 6,509,348 (Ogletree), the disclosures of which are hereby incorporated by reference in their entireties. These may include, but are not limited to, interphenylene 7-oxabicyclo-heptyl substituted heterocyclic amide prostaglandin analogs as disclosed in U.S. Pat. No. 5,100,889, including:
- [1S-(1α, 2α, 3α, 4α)]-2-[3-[4-[(4-cyclo-hexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]-hept-2-yl]methyl]benzenepropanoic acid (SQ 33,961), or esters or salts thereof;
- [1S-(1α, 2α, 3α, 4α)]-2-[3-[4-[[(4-chloro-phenyl)-butyl] amino] carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid or esters, or salts thereof;
- [1S-(1α, 2α, 3α, 4α)]-3-[3-[4-[(4-cycloh-exylbutyl)-amino]carbonyl]-2-oxazolyl]-7-oxabicyclo]2.2.1]hept-2-yl]benzene acetic acid, or esters or salts thereof;
- [1S-(1α, 2α, 3α, 4α)]-[2-[3-[4-[(4-cyclohexyl-butyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]phenoxy]acetic acid, or esters or salts thereof;
- [1S-(1α, 2α, 3α, 4α]-2-[3-[4-[(7,7-dime-thyloctyl)-amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-methyl]benzenepropanoic acid, or esters or salts thereof
- 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs as disclosed in U.S. Pat. No. 5,100,889, issued Mar. 31, 1992, including [1S-[1α, 2α (Z), 3α, 4α)]-[6[3-[4-[(4-cyclohexylbutyl)amino]-carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1] hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α)]]-6-[3-[4-[(4-cyclohexyl-butyl)amino]carbonyl]-2-thiazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α)]]-6-[3-[4-[(4-cyclohexyl-butyl)methylamino]carbonyl]-2-oxazolyl]-7-oxabicyclo-[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α)]]-6-[3[4-[(1-pyrrolidinyl)-carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α)]]-6-[3[4-[(cyclohexylamino)-carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl-4-hexenoic acid or esters or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α)]]-6-[3[4-[(2-cyclohexyl-ethyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α)]]-6-[3[4-[[2-(4-chloro-phenyl)ethyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo-[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α)]-[6[3-[4-[(4-chlorophenyl)-amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α)]]-6-[3[4-[[4-(4-chloro-phenyl)butyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo-[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- [1S-[1 1α, 2α (Z), 3α, 4α)]]-[6[3-[4.alpha.-[-(6-cyclohexyl-hexyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters, or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α)]]-6-[3-[4-[(6-cyclohexyl-hexyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α]]-[6[3-[4-[(propylamino)-carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof
- [1S-[1α, 2α (Z), 3α, 4α)]]-6-[3[4-[(4-butylphenyl)-amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α)]]-6-[3[4-[(2,3-dihydro-1H-indol-1-yl)carbonyl]-2-oxazolyl]-7-oxabicyclo(2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α)]]-6-[3[4-[(4-cyclohexyl-butyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-N-(phenylsulfonyl)-4-hexenamide;
- [1S-[11α, 2α (Z), 3α, 4α)]]-6-[3[4-[(4-cyclohexyl-butyl)amino]carbonyl]-2-oxazolyl]-N-(methylsulfonyl)-7-oxabicyclo[2-.2.1]hept-2-yl]-4-hexenamide;
- [1S-[1α, 2α (Z), 3α, 4α)]]-7-[3-[4-[(4-cyclohexyl-butyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo(2.2.1]hept-2-yl]-5-heptenoic acid, or esters or salts thereof;
- [1S-[1α, 2α (Z), 3α, 4α)]]-[6[3-[4-[(4-cyclohexyl-butyl)amino]carbonyl]-1H-imidazol-2-yl]-7-oxabicyclo-[2.2.1]hept-2-yl]-4-hexenoic acid or esters or salts thereof;
- [1S-[1α, 2α, 3α, 4α)]-6-[3-[4-[(7,7-dimethyloctyl)-amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- [1S-[1α, 2α(E), 3α, 4α)]]-6-[3-[4-[(4-cyclohexyl-butyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid;
- [1S-[1α, 2α, 3α, 4α)]-3-[4-[(4-(cyclohexylbutyl)-amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]heptane-2-hexanoic acid or esters or salts thereof,
- [1S-[1α, 2α(Z), 3α, 4α)]]-6-[3-[4-[(4-cyclohexyl-butyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo-[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;
- 7-oxabicycloheptane and 7-oxabicycloheptene compounds disclosed in U.S. Pat. No. 4,537,981 to Snitman et al, the disclosure of which is hereby incorporated by reference in its entirety, such as [1S-(1α, 2α(Z), 3α,4α)]]-743-(3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (SQ 29,548); the 7-oxabicycloheptane substituted aminoprostaglandin analogs disclosed in U.S. Pat. No. 4,416,896 to Nakane et al, the disclosure of which is hereby incorporated by reference in its entirety, such as [1S-[1α, 2α(Z), 3α, 4α)]]-7-[34[2-(phenylamino)carbonyl]-hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid; the 7-oxabicycloheptane substituted diamide prostaglandin analogs disclosed in U.S. Pat. No. 4,663,336 to Nakane et al, the disclosure of which is hereby incorporated by reference in its entirety, such as, [1S-[1α, 2α(Z), 3α, 4α]]-7-[[[[(1-oxoheptyl)amino]-acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid and the corresponding tetrazole, and [1S-[ 1α, 2α(Z), 3α,4α)]]-7-[3-[[(4-cyclohexyl-1-oxobutyl)-amino]acetyl]amino]methyl]-7-oxabicyclo]2.2.1]hept-2-yl]-5-heptenoic acid;
- 7-oxabicycloheptane imidazole prostaglandin analogs as disclosed in U.S. Pat. No. 4,977,174, the disclosure of which is hereby incorporated by reference in its entirety, such as [1S-[1α, 2α(Z), 3α, 4α)]]-6-[3-[4-(4-cyclohexyl-1-hydroxybutyl)-1H-imidazole-1-yl] methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid or its methyl ester;
- [1S-[1α, 2α(Z), 3α, 4α)]]-6-[3-[4-(3-cyclohexyl-propyl)-1H-imidazol-1-yl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid or its methyl ester;
- [1S-[1a., 2α(X(Z), 3α, 4α)]]-6-[3-[4-(4-cyclohexyl-1-oxobutyl)-1H-imidazol-1-yl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid or its methyl ester;
- [1S-[1α, 2α(Z), 3α, 4α]]-[6[3-(1H-imidazol-1-ylmethyl)-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid or its methyl ester; or
- [1S-[ 1α, 2α(Z), 3α, 4α)]]-6-[3-[4-[(4-cyclohexyl-butyl)amino]carbonyl]-1H-imidazol-1-yl]methyl-7-oxabicyclo-[2.2.1]-hept-2-yl]-4-hexenoic acid, or its methyl ester;
- The phenoxyalkyl carboxylic acids disclosed in U.S. Pat. No. 4,258,058 to Witte et al, the disclosure of which is hereby incorporated by reference in its entirety, including 4-[2-(benzenesulfamido)ethyl]phenoxy-acetic acid (BM 13,177-Boehringer Mannheim), the sulphonamidophenyl carboxylic acids disclosed in U.S. Pat. No. 4,443,477 to Witte et al, the disclosure of which is hereby incorporated by reference in its entirety, including 4-[2-(4-chlorobenzenesulfonamido)ethyl]-phenylacetic acid (BM 13,505, Boehringer Mannheim), the arylthioalkylphenyl carboxylic acids disclosed in U.S. Pat. No. 4,752,616, the disclosure of which is hereby incorporated by reference in its entirety, including 4-(3-((4-chlorophenyl)sulfonyl)propyl)benzene acetic acid.
- Other examples of thromboxane A2 receptor antagonists suitable for use herein include, but are not limited to vapiprost (which is a preferred example), (E)-5-[[(pyridinyl)]3-(trifluoromethyl)phenyl]methylene]amino]-oxy]pentanoic acid also referred to as R68,070-Janssen Research Laboratories, 3-[1-(4-chlorophenylmethyl)-5-fluoro-3-methylindol-2-yl]-2,-2-dimethylpropanoic acid [(L-655240 Merck-Frosst) Eur. J. Pharmacol. 135(2):193, Mar. 17, 87], 5(Z)-7-([2,4,5-cis]-4-(2-hydroxyphenyl)-2-trifl-uoromethyl-1,3-dioxan-5-yl)heptenoic acid (ICI 185282, Brit. J. Pharmacol. 90 (Proc. Suppl):228 P-Abs, March 87), 5(Z)-7-[2,2-dimethyl-4-phenyl-1,3-dioxan-cis-5-yl]heptenoic acid (ICI 159995, Brit. J. Pharmacol. 86 (Proc. Suppl):808 P-Abs., December 85), N,N′-bis[7-(3-chlorobenzeneamino-sulfony-1)-1,2,3,4-tetrahydro-isoquinolyl]disulfonylimide (SKF 88046, Pharmacologist 25(3):116 Abs., 117 Abs, August 83), (1.alpha.(Z)-2.beta., 5.alpha.]-(+)-7-[5-[(1,1′-biphenyl)-4-yl]-methoxy]-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid (AH 23848-Glaxo, Circulation 72(6):1208, December 85, levallorphan allyl bromide (CM 32,191 Sanofi, Life Sci. 31 (20-21):2261, Nov. 15,82), (Z,2-endo-3-oxo)-7-(3-acetyl-2-bicyclo[2.2.1]heptyl-5-hepta-3Z-enoic acid, 4-phenyl-thiosemicarbazone (EP092-Univ. Edinburgh, Brit. J. Pharmacol. 84(3):595, March 85); GR 32,191 (Vapiprost)-[1R-[1.alpha.(Z), 2.beta., 3.beta., 5.alpha.]]-(+)-7-[5-([1,1′-biphenyl]-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid; ICI 192,605-4(Z)-6-[(2,4,5-cis)2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]hexenoic acid; BAY u 3405 (ramatroban)-3-[(4-fluorophenyl)-sulfonyl]amino]-1,2,3,4-tetrahydro-9H-c-arbazole-9-propanoic acid; or ONO 3708-7-[2.alpha., 4.alpha.-(dimethylmethano)-6.beta.-(2-cyclopentyl-2.beta.-hydroxyacetami-do)-1.alpha.-cyclohexyl]-5(Z)-heptenoic acid; (.+-.)(5Z)-7-[3-endo-((phenylsulfonyl)amino]-bicyclo[2.2.1]hept-2-exo-yl]-heptenoic acid (S-1452, Shionogi domitroban, Anboxan®.); (−)6,8-difluoro-9-p-methylsulfonylben-zyl-1,2,3,4-tetrahydrocarbazol-1-yl-acetic acid (L670596, Merck) and (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]-2,2-dimethylpropanoic acid (L655240, Merck).
- The preferred thromboxane A2 receptor antagonist of the present invention is ifetroban or any pharmaceutically acceptable salts thereof.
- In certain preferred embodiments the preferred thromboxane A2 receptor antagonist is ifetroban sodium (known chemically as [1S-(1α,2α,3α,4α)]-2-[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt.
- In certain embodiments, the AERD and/or asthma is treated via the administration of a thromboxane receptor antagonist (e.g., a thromboxane A2 receptor antagonist) ranging from about 0.1 ng/ml to about 10,000 ng/ml. Preferably, the plasma concentration of thromboxane receptor antagonist ranges from about 1 ng/ml to about 1,000 ng/ml, preferably from about 1.0 ng/ml to about 6000 ng/ml, or from about 40 ng/ml to about 3500 ng/ml, or from about 300 ng/ml to about 2500 ng/ml.
- In certain preferred embodiments, the thromboxane A2 receptor antagonist is ifetroban or a pharmaceutically acceptable salt thereof (e.g., ifetroban sodium) and the dose administered orally to human patients is from about 150 mg/day to about 400 mg/day, administered in one dose or divided doses. In certain preferred embodiments, the thromboxane A2 receptor antagonist is ifetroban sodium and the dose is about 200 mg/day when administered orally to a human patient(s) suffering from AERD and/or asthma.
- When the thromboxane A2 receptor antagonist is ifetroban, the desired plasma concentration for providing a therapeutic effect for the treatment of AERD and/or asthma should be greater than about 10 ng/mL (ifetroban free acid). Some therapeutic effect of thromboxane A2 receptor antagonist, e.g., ifetroban, may be seen at concentrations of greater than about 1 ng/mL.
- The dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.
- However, in order to obtain the desired plasma concentration of thromboxane A2 receptor antagonists, daily doses of the thromboxane A2 receptor antagonists ranging from about 0.1 mg to about 5000 mg should be administered. Preferably, the daily dose of thromboxane A2 receptor antagonists ranges from about 1 mg to about 1000 mg; about 10 mg to about 1000 mg; about 50 mg to about 500 mg; about 100 mg to about 500 mg; about 200 mg to about 500 mg; about 300 mg to about 500 mg; and about 400 mg to about 500 mg per day.
- In certain preferred embodiments, a daily dose of ifetroban sodium from about 10 mg to about 250 mg (ifetroban free acid amounts) will produce effective plasma levels of ifetroban free acid.
- The thromboxane A2 receptor antagonists of the present invention may be administered by any pharmaceutically effective route. For example, the thromboxane A2 receptor antagonists may be formulated in a manner such that they can be administered orally, intranasally, rectally, vaginally, sublingually, buccally, parenterally, or transdermally, and, thus, be formulated accordingly.
- In certain embodiments, the thromboxane A2 receptor antagonists may be formulated in a pharmaceutically acceptable oral dosage form. Oral dosage forms may include, but are not limited to, oral solid dosage forms and oral liquid dosage forms.
- Oral solid dosage forms may include, but are not limited to, tablets, capsules, caplets, powders, pellets, multiparticulates, beads, spheres and any combinations thereof. These oral solid dosage forms may be formulated as immediate release, controlled release, sustained (extended) release or modified release formulations.
- The oral solid dosage forms of the present invention may also contain pharmaceutically acceptable excipients such as fillers, diluents, lubricants, surfactants, glidants, binders, dispersing agents, suspending agents, disintegrants, viscosity-increasing agents, film-forming agents, granulation aid, flavoring agents, sweetener, coating agents, solubilizing agents, and combinations thereof
- Depending on the desired release profile, the oral solid dosage forms of the present invention may contain a suitable amount of controlled-release agents, extended-release agents, modified-release agents.
- Oral liquid dosage forms include, but are not limited to, solutions, emulsions, suspensions, and syrups. These oral liquid dosage forms may be formulated with any pharmaceutically acceptable excipient known to those of skill in the art for the preparation of liquid dosage forms. For example, water, glycerin, simple syrup, alcohol and combinations thereof.
- In certain embodiments of the present invention, the thromboxane A2 receptor antagonists may be formulated into a dosage form suitable for parenteral use. For example, the dosage form may be a lyophilized powder, a solution, suspension (e.g., depot suspension).
- In other embodiments, the thromboxane receptor antagonists may be formulated into a topical dosage form such as, but not limited to, a patch, a gel, a paste, a cream, an emulsion, liniment, balm, lotion, and ointment.
- A significant proportion of patients that suffer from asthma take one or more medications on a daily (chronic) basis in order to prevent or attenuate symptoms of asthma. Such drugs include corticosteroids (including but not limited to inhaled corticosteroids), Cromolyn, Omalizumab, short or long-acting beta-2 agonists (typically inhaled), leukotriene modifiers (e.g., zafirlukast (Accolate®), montelukast (Singulair®), and zileuton (Zyflo®)), and theophylline. Advair (a combination drug that includes a steroid and a long-acting bronchodilator drug). Inhaled steroid medications include but are not limited to the following: Aerobid®, Asmanex®, Azmacort®, Dulera® (a combination drug that also includes a long-acting bronchodilator drug), Flovent®, Pulmicort®, Symbicort® (a combination drug that includes a steroid and a long-acting bronchodilator drug), Qvar®, and the like. Inhaled steroids come in three forms: the metered dose inhaler (MDI), dry powder inhaler (DPI), and nebulizer solutions. Omalizumab (trade name Xolair®, Roche/Genentech and Novartis) is a humanized antibody originally designed to reduce sensitivity to inhaled or ingested allergens, especially in the control of moderate to severe allergic asthma, which does not respond to high doses of corticosteroids. In certain embodiments, the present method of treatment further contemplates combination therapy comprising administering a thromboxane receptor antagonist and one or more of the above drugs to a human patient suffering from AERD and/or asthma.
- The following examples are not meant to be limiting and represent certain embodiments of the present invention.
- In this example, ifetroban sodium tablets are prepared with the following ingredients listed in Table 1:
-
TABLE 1 Ingredients Percent by weight Na salt of Ifetroban 35 Mannitol 50 Microcrystalline Cellulose 8 Crospovidone 3.0 Magnesium Oxide 2.0 Magnesium Stearate 1.5 Colloidal Silica 0.3 - The sodium salt of ifetroban, magnesium oxide, mannitol, microcrystalline cellulose, and crospovidone is mixed together for about 2 to about 10 minutes employing a suitable mixer. The resulting mixture is passed through a #12 to #40 mesh size screen. Thereafter, magnesium stearate and colloidal silica are added and mixing is continued for about 1 to about 3 minutes.
- The resulting homogeneous mixture is then compressed into tablets each containing 35 mg, ifetroban sodium salt.
- In this example, 1000 tablets each containing 400 mg of Ifetroban sodium are produced from the following ingredients listed in Table 2:
-
TABLE 2 Ingredients Amount Na salt of Ifetroban 400 gm Corn Starch 50 g Gelatin 7.5 g Microcrystalline Cellulose (Avicel) 25 g Magnesium Stearate 2.5 g - In this example. An injectable solution of ifetroban sodium is prepared for intravenous use with the following ingredients listed in Table 3:
-
TABLE 3 Ingredients Amount Ifetroban Sodium 2500 mg Methyl Paraben 5 mg Propyl Paraben 1 mg Sodium Chloride 25,000 mg Water for injection q.s. 5 liter - The sodium salt of ifetroban, preservatives and sodium chloride are dissolved in 3 liters of water for injection and then the volume is brought up to 5 liters. The solution is filtered through a sterile filter and aseptically filled into pre-sterilized vials which are then closed with pre-sterilized rubber closures. Each vial contains a concentration of 75 mg of active ingredient per 150 ml of solution.
- Example IV is a multicenter, double-blind, randomized, placebo-controlled trial to determine the safety of oral ifetroban in patients with a history of aspirin exacerbated respiratory disease (AERD).
- The eligible subjects were randomized (3:1 active to placebo) in this 7-day study which consisted of a screening, treatment and follow-up period. Any subject receiving at least a partial dose of IMP were not replaced and included in the study analysis. Of 19 subjects enrolled and randomized to study treatment, 14 (74%) were randomized to the ifetroban group and 5 (26%) to the placebo group. Of those 14 randomized to ifetroban, 12 (86%) subjects were treated and 100% of those treated completed treatment. Of 5 subjects randomized to placebo, 4 (80%) started treatment and 100% completed treatment. All treated subjects were analyzed for safety and efficacy variables.
- A placebo treatment arm was included in this study to provide data on the spontaneous response rate of AERD subjects, as well as to help identify any safety or efficacy signals in the subjects receiving ifetroban. In numerous trials, subjects with asthma assigned to placebo have demonstrated improvement in symptoms, quality of life, and even in lung function, such as FEV1. In general, the placebo effect in asthma can be as great as 30 to 50% depending on which endpoint is chosen (Castro, 2007; Placebo versus Best-Available-Therapy Control Group in Clinical Trials for Pharmacologic Therapies. Proceedings of the American Thoracic Society, 570-573).
- All individuals with AERD will experience a clinical reaction to aspirin, most often at a dose of 81 mg or below. By utilizing a modified Scripps Institute protocol (Hope, Woessner, Simon, & Stevenson, 2009), limiting the study to individuals with stable asthma and no history of life-threatening reaction to COX inhibitors and administering the cysteinyl leukotriene receptor 1 (Cys-LT1) antagonist montelukast to all individuals undergoing the challenge/desensitization, the procedure could safely be done in an ambulatory/outpatient clinic setting. The results of a study published in 2006 (White, Ludington, Mehra, Stevenson, & Simon, 2006), demonstrated that leukotriene modifier drugs, like montelukast, had a significant effect in protecting the lower airways from severe reactions (P=0.004) in subjects undergoing aspirin challenge/desensitization. Thus, montelukast substantially increases the safety of aspirin challenge/desensitization and it is the standard of care to use montelukast as a pre-treatment for subjects with AERD undergoing a planned aspirin challenge/desensitization. Because montelukast does not inhibit CYP2C9 or CYP3A4, montelukast was not expected to affect the elimination of ifetroban.
- The primary objective of this study was to determine the safety of oral ifetroban compared to placebo as measured by a≥20% decrease in Forced Expiratory Volume in 1 second (FEV1) compared to baseline following a dose of Investigational Medicinal Product (IMP) (Study Day 1) or following a dose of IMP but prior to initiation of the aspirin challenge. Secondary objectives were: (i) to determine the safety of oral ifetroban compared to placebo as measured by peak Nasal Inspiratory Flow Rate (NIFR) compared to baseline following a dose of IMP (Study Day 1) or following a dose of IMP but prior to initiation of the aspirin challenge; (ii) to determine the safety of oral ifetroban compared to placebo as measured by the change in Total Nasal Symptom Score (TNSS) compared to baseline following a dose of IMP (Study Day 1) or following a dose of IMP but prior to initiation of the aspirin challenge; (iii) to determine the safety and tolerability of oral ifetroban compared to placebo as measured by treatment-emergent adverse events; (iv) to determine the efficacy of oral ifetroban compared to placebo in decreasing the respiratory reaction to oral aspirin as measured by the change in FEV1 compared to baseline during the aspirin challenge; (v) to determine the efficacy of oral ifetroban compared to placebo in decreasing the respiratory reaction to oral aspirin as measured by the change in NIFR compared to baseline during the aspirin challenge; (vi) to determine the efficacy of oral ifetroban compared to placebo in decreasing the respiratory reaction to oral aspirin as measured by the change in TNSS compared to baseline during the aspirin challenge; (vii) to determine the efficacy of oral ifetroban compared to placebo in decreasing the respiratory reaction to oral aspirin as measured by the amount of rescue medication during the aspirin challenge; (viii) to determine the efficacy of oral ifetroban compared to placebo in decreasing respiratory sensitivity to COX-1 inhibition as measured by the aspirin desensitization dose level; and (ix) to determine the efficacy of oral ifetroban compared to placebo as measured by the number of asthmatic reactions during the Treatment Period.
- The main criteria for inclusion in the study were adults with a history of physician-diagnosed stable asthma (FEV1 of at least 1.25 Liters (L) and 60% or better than predicted (calculated by spirometer based on gender, age, etc.) on two previous visits with no more than a 10% variation in those values, no increase in baseline dose of oral glucocorticoids for asthma for at least three months, and no history of hospitalization or emergency room visits for asthma for at least the prior six months), who have a history of nasal polyposis and have a history of at least one clinical reaction to oral aspirin or other nonselective cyclooxygenase (COX) inhibitor with features of lower (cough, chest tightness, wheezing, dyspnea) and/or upper (rhinorrhea, sneezing, nasal obstruction, conjunctival itching and discharge) airway involvement, and who are currently receiving montelukast (at least 10 mg per day, oral) or zafirlukast (at least 20 mg, twice per day, oral), with at least 1 week of therapy prior to receiving the first dose of the investigational medicinal product (IMP).
- Subjects were allowed to enter the trial on the following medications: oral corticosteroids at a dose of <10 mg/day prednisone or prednisone equivalent, inhaled/nasal corticosteroids, inhaled long-acting β-adrenergic agonists and inhaled ipratropium; however, no modifications were allowed during the study except for a temporary increase in the dose of oral corticosteroids if asthma worsened requiring such intervention. Subjects were required to stop using short-acting β-adrenergic agonists 24 hours prior, nasal decongestants and antihistamines 48 hours prior to first dose of IMP and throughout the study unless asthma worsened requiring such intervention.
- Oral, nasal, inhaled corticosteroids and inhaled long acting beta-adrenergic agonists and inhaled ipratropium were allowed to be used during the study without modification to the subject's dosing regimen if the subject entered the trial on such medications. It is believed that these medications would not mask a potential response to the aspirin challenge. Inhaled short acting beta-adrenergic agonists, nasal decongestants, and antihistamines were not allowed for specified periods prior to the study and through the initiation of the aspirin challenge as these medications may mask a potential response and thus affect the study efficacy endpoints. Warfarin, antiplatelet, or anticoagulant medications were prohibited 2 weeks prior to enrollment and during the course of the study.
- The primary efficacy variable assessed was FEV1 measured by spirometry. Secondary efficacy variables included the NIFR using a Youlten meter (or similar), and the subject-completed questionnaire, Total Nasal Symptom Score (TNSS). Additional efficacy variables were the incidence of asthmatic reactions, the incidence of respiratory reactions to oral aspirin, the amount of medications used to manage an aspirin-induced reaction and the aspirin dose at which a reaction was provoked during the desensitization process.
- The treatment period consisted of a phase A assessing safety and efficacy of IMP administered
Day 1 and Day 2 followed by a phase B assessing safety and efficacy of IMP during the aspirin challenge on Day 2 and Day 3. Subjects experiencing a decrease in FEV1 of ≥20% during phase A would not continue to phase B of the study. The follow-up period started upon completion of the aspirin challenge and ended on Day 7 with a phone call to assess for safety. All subjects were required to be taking either oral montelukast or zafirlukast (at least 10 mg/day or 20 mg twice per day, respectively) one week prior to the study and for the duration of the study. Ifetroban was supplied as 50-mg ifetroban sodium capsules and orally administered at a dose of 200 mg every 24 hours for three consecutive days. Identically appearing placebo capsules were provided for blinding purposes and 4 capsules administered orally every 24 hours for 3 consecutive days. The duration of IMP treatment was 3 days. The study duration was 7 days. - No subject met this primary endpoint therefore all subjects continued to phase B of the study. No subject experienced a≥20% decrease in FEV1 during the aspirin challenge (phase B). At baseline, FEV1 was comparable between treatment groups (Table 8 and Table 10). Mean changes from baseline FEV1 remained well below 20% throughout the treatment period in both treatment groups. No clear trends were observed between treatment groups. At baseline, FEV1 was comparable between treatment groups. Mean changes from baseline FEV1 remained well below 20% throughout the treatment period in both treatment groups. No clear trends were observed between treatment groups.
- Safety evaluations included spirometry, NIFR, TNSS, adverse events, & vital signs. No serious adverse events (SAE) or treatment-emergent SAEs were reported.
- Additional secondary objectives included evaluating the treatment groups for the proportion of subjects with a≥25% decrease in peak NIFR (nasal inspiratory flow rate) and the proportion of subjects with a≥25%, 50% and 75% increase in TNSS (total nasal symptom score) during phase A and phase B. The results are further described in Table 4 below:
-
TABLE 4 Changes from Baseline in NIFR and TNSS during Phase A and Phase B No. of Phase A Phase B Phase C Subjects Ifetroban Placebo Ifetroban Placebo Ifetroban Placebo (%) n = 12 n = 4 n = 12 n = 4 n = 12 n = 4 NIFR ≥25% 2(17) 1(25) 4(33) 1(25) 5(42) 1(25) decrease ≥25% 3(25) 0 7(58) 2(50) 9(75) 2(50) increase TNSS ≥25% 0 0 3(25) 1(25) 3(25) 1(25) increase ≥25% 1(8) 0 2(17) 0 2(17) 0 decrease NIFR = nasal inspiratory flow rate, TNSS = total nasal symptom score; *Overall number of subjects may be less than the sum of subjects in phase A and phase B columns since a subject that experienced an event during phase A and phase B is counted twice. * Overall number of subjects may be less than the sum of subjects in phase A and phase B columns since a subject that experienced an event during phase A and phase B is counted twice - Overall there were 6 (38%) subjects that experienced a≥25% decrease in peak NIFR, and 4 (25%) subjects that experienced a≥25% increase in TNSS during the study. As expected, these events occurred mainly in phase B during the aspirin desensitization process. Five (42%) subjects receiving ifetroban and 1 (25%) subject receiving placebo experienced a≥25% decrease in peak NIFR during the study. One subject in each treatment arm experienced a≥25% decrease in peak NIFR during both phase A and phase B. No one experienced a≥50% or 75% increase or decrease in TNSS during the study. No subject experienced a≥25% increase in TNSS during phase A.
- Conversely, 1 (8%) subject during phase A and 2 (17%) subjects during phase B experienced a≥25% decrease in TNSS but only in the ifetroban arm. No subject on placebo experienced a≥25% decrease in TNSS during the study. There were 9 (75%) subjects receiving ifetroban and 2 (50%) subjects receiving placebo that experienced a≥25% increase in peak NIFR during the study. These increases in peak NIFR occurred mainly in phase B during the aspirin desensitization process. While no clear trends were observed in the proportion of subjects with worsening NIFR or TNSS between treatment groups, there is an observed trend in favor of the ifetroban group toward greater improvements to NIFR and TNSS during phase A and phase B.
- No asthmatic reactions were reported or rescue medications used during phase A prior to aspirin initiation. For this reason, all 16 subjects treated with IMP continued to phase B. Rescue medication was only administered as a result of an aspirin-induced reaction (AIR) during the aspirin desensitization process and no subject required rescue medication outside the clinic for an asthmatic reaction throughout the 7-day study period. Two (17%) subjects on ifetroban and 1 (25%) subject on placebo did not experience an AIR during the aspirin desensitization process hence no rescue medication was administered to these 3 (19%) subjects. 1 (10%) subject on the ifetroban arm experienced an AIR yet required no rescue medication to resolve symptoms. All 3 (100) subjects on the placebo arm that experienced an AIR required rescue medications and a greater number of medications on average were needed to resolve their symptoms compared to subjects on ifetroban that experienced an AIR. The amount of rescue medication required during the aspirin challenge (phase B) was evaluated as a secondary efficacy endpoint. Subjects on the placebo arm required, on average, 7.33 rescue medications to resolve an aspirin-induced reaction (AIR), while subjects on ifetroban required a mean of 2.90 rescue medications, a 2.5 fold difference. There is a trend toward fewer rescue medications in favor of the ifetroban group. A summary of AIRs and Rescue medication use is provided in Table 5 below:
-
TABLE 5 Summary of AERD Phase 2a Data: AIRs and Rescue Medication Use No. of Subjects (%) Ifetroban Placebo All Subjects n = 12 n = 4 n = 16 Aspirin-induced Reaction (AIR) Yes 10 (83) 3 (75) 13 (81) No 2 (17) 1 (25) 3 (19) Required Rescue Medication* Yes 9 (90) 3 (100) 12 (92) No 1 (10) 0 1 (8) Total Number of 29 22 51 Rescue Medications Mean (SD) 2.90 (2.02) 7.33 (3.79) 3.92 (3.04) Median* 3 9 3 Min, Max* 0, 7 3, 10 0, 10 - There is a trend toward fewer rescue medications in favor of the ifetroban group.
- The incidence of the AIR provoked at each aspirin dose was evaluated between treatment groups and summarized in this table. All subjects who experienced an AIR reacted to a provoking dose of 60 and/or 100 mg. No reaction occurred after the 100-mg provoking dose. All initial reactions in the placebo arm occurred at the 60-mg dose while in the ifetroban arm, 50% of the initial reactions occurred at 60-mg and the other half at 100-mg. One subject on placebo experienced a provoking dose reaction at 60 mg on Day 2 and another AIR on Day 3 at 100 mg. The severity of the 2 AIRs were comparable to one another. All other subjects experienced a single AIR during the aspirin desensitization process. Further information concerning AERD Phase 2αAIRs by aspirin dose is presented in Table 6 below.
-
TABLE 6 Incidence of an AIR by Aspirin Dose No. of Subjects (%)* Ifetroban Placebo All AIR Subjects n = 10 n = 3** N = 13 Aspirin Dose (mg) 30 0 0 0 60 5(50) 3(100) 8(62) 100 5(50) 1(25) 6(46) 150 0 0 0 325 0 0 0 *Based on AIR population only; **1 subject experienced 1 AIR at 60 mg and 1 AIR at 100 mg hence counted twice. AlR = Aspirin-induced Reaction - The incidence of the AIR provoked at each aspirin dose was evaluated between treatment groups and summarized in Table 6. All subjects who experienced an AIR reacted to a provoking dose of 60 and/or 100 mg. No reaction occurred after the 100-mg provoking dose. All initial reactions in the placebo arm occurred at the 60-mg dose while in the ifetroban arm, 50% of the initial reactions occurred at 60-mg and the other half at 100-mg. One subject on placebo experienced a provoking dose reaction at 60 mg on Day 2 and another AIR on Day 3 at 100 mg. The severity of the 2 AIRs were comparable to one another. All other subjects experienced a single AIR during the aspirin desensitization process.
- The severity of the AIRs were compared between treatment groups by the number of separate symptoms that manifested during the aspirin challenge. The total number of symptoms are based on 14 AIRs that occurred in 13 subjects, 10 ifetroban-treated subjects and 3 placebo-treated subjects. As mentioned previously, 1 subject on the placebo arm experienced 2 AIRs. The average number of symptoms per AIR was comparable between treatment groups. Both arms experienced a bronchial reaction (<20% decrease in FEV1, wheezing, chest tightness) as part of the AIR at a similar rate. While an upper respiratory effect (rhinorrhea, nasal obstruction, sneezing) was equally as common between treatment groups, an ocular manifestation seems to trend toward the placebo arm more often than on the ifetroban arm. AIR severity in the study is reported in Table 7 below.
-
TABLE 7 Severity of an AIR by Clinical Manifestation Category/Feature Ifetroban Placebo All AIR Subjects n = 10 n = 3 N = 13 All Symptoms* 43 20 63 Mean(SD) 4.3(1.34) 5.00(0.82) 4.50(1.22) Median 4 5 4 Min, Max 3.7 4.6 3.7 <20% decrease in 9 4 13 FEVI Mean 0.9 1 1 Upper Respiratory 25 11 36 Mean 2.5 2.8 2.6 Lower Respiratory 13 5 18 Mean 1.3 1.3 1.3 Ocular 5 4 9 Mean 0.5 1 0.6 - In conclusion, in this clinical study, ifetroban at 200 mg/day was shown to be well tolerated and safe in subjects with a history of AERD. There was no increase in AEs reported in the ifetroban group compared to placebo. All subjects completed treatment and aspirin desensitization. The primary endpoint was met; ifetroban did not cause a≥20% decrease in FEV1. The results of this small safety study demonstrated that ifetroban was safe when administered to patients with AERD. In addition, results from the study suggest the symptoms of aspirin desensitization in AERD patients may be diminished by the use of ifetroban at a dose of 200 mg/day.
- The primary endpoint was not met; ifetroban did not cause a≥20% decrease in FEV1 during the course of IMP treatment or the aspirin desensitization process. Mean changes from baseline FEV1 remained well below 20% throughout the treatment period in both groups with no clear trends observed. While no appreciable difference was observed in the proportion of subjects with worsening NIFR or TNSS between treatment groups, there is an observed trend in favor of the ifetroban group toward greater improvements to NIFR and TNSS during phase A and phase B. Moreover, there is an apparent trend toward fewer rescue medications in favor of the ifetroban group and, while an upper respiratory effect was equally as common between treatment groups, an ocular manifestation seems to trend toward the placebo arm more often than on the ifetroban arm. Although the sample size is not sufficient to demonstrate statistically significant treatment efficacy, these data are encouraging. Larger studies with longer treatment duration are needed to make formal conclusions about ifetroban efficacy in AERD. The results of this small safety study support further investigations of ifetroban at a therapeutic dose of 200 mg/day for subjects with AERD.
- In the preceding specification, the invention has been described with reference to specific exemplary embodiments and examples thereof It will, however, be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the invention as set forth in the claims that follow. The specification and drawings are accordingly to be regarded in an illustrative manner rather than a restrictive sense.
- Armour C L, Johnson P R, Alfredson M L, Black J L. Characterization of contractile prostanoid receptors on human airway smooth muscle. Eur J Pharmacol 1989
Jun 20;165(2-3):215-22. - Bochenek G, Nagraba K, Nizankowska E, Szczeklik A. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003 Apr;111(4):743-9.
- Fischer A R, Rosenberg M A, Lilly C M, Callery J C, Rubin P, Cohn J, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994 Dec;94(6 Pt 1):1046-56.
- Laidlaw T M, Kidder M S, Bhattacharyya N, Xing W, Shen S, Milne G L, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 2012 Apr 19;119(16):3790-8.
- Liu T, Laidlaw T M, Feng C, Xing W, Shen S, Milne G L, et al. Prostaglandin E2 deficiency uncovers a dominant role for thromboxane A2 in house dust mite-induced allergic pulmonary inflammation. Proc Natl Acad Sci USA 2012 Jul 31;109(31):12692-7.
- Liu T, Laidlaw T M, Katz H R, Boyce J A. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci USA 2013 Oct 15;110(42):16987-92.
- Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000
Oct 20;275(42):32783-92. - Ogletree M L, Allen G T. Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles. J Pharmacol Exp Ther. 1992 February;260(2):789-94.
- Pettipher R, Hansel T T, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007 Apr;6(4):313-25.
- Picado C, Fernandez-Morata J C, Juan M, Roca-Ferrer J, Fuentes M, Xaubet A, et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1999 Jul;160(1):291-6.
- Sladek K, Dworski R, Soja J, Sheller J R, Nizankowska E, Oates J A, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994 Apr;149(4 Pt 1):940-6.
- Sousa A, Pfister R, Christie P E, Lane S J, Nasser S M, Schmitz-Schumann M, et al Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax 1997 Nov;52(11):940-5.
- Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, Sheller J, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996 Dec;154(6 Pt 1):1608-14.
- Yoshimura T, Yoshikawa M, Otori N, Haruna S, Moriyama H. Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma. Allergol Int 2008 Dec;57(4):429-36.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/705,522 US20220211674A1 (en) | 2015-06-30 | 2022-03-28 | Thromboxane Receptor Antagonists in AERD/Asthma |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562186644P | 2015-06-30 | 2015-06-30 | |
US15/195,265 US20170000771A1 (en) | 2015-06-30 | 2016-06-28 | Thromboxane Receptor Antagonists in AERD/Asthma |
US16/687,151 US11571412B2 (en) | 2015-06-30 | 2019-11-18 | Thromboxane receptor antagonists in AERD/asthma |
US17/705,522 US20220211674A1 (en) | 2015-06-30 | 2022-03-28 | Thromboxane Receptor Antagonists in AERD/Asthma |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/687,151 Continuation US11571412B2 (en) | 2015-06-30 | 2019-11-18 | Thromboxane receptor antagonists in AERD/asthma |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220211674A1 true US20220211674A1 (en) | 2022-07-07 |
Family
ID=57609035
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/195,265 Abandoned US20170000771A1 (en) | 2015-06-30 | 2016-06-28 | Thromboxane Receptor Antagonists in AERD/Asthma |
US16/687,151 Active 2036-07-23 US11571412B2 (en) | 2015-06-30 | 2019-11-18 | Thromboxane receptor antagonists in AERD/asthma |
US17/705,557 Abandoned US20220218672A1 (en) | 2015-06-30 | 2022-03-28 | Thromboxane Receptor Antagonists in AERD/Asthma |
US17/705,522 Abandoned US20220211674A1 (en) | 2015-06-30 | 2022-03-28 | Thromboxane Receptor Antagonists in AERD/Asthma |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/195,265 Abandoned US20170000771A1 (en) | 2015-06-30 | 2016-06-28 | Thromboxane Receptor Antagonists in AERD/Asthma |
US16/687,151 Active 2036-07-23 US11571412B2 (en) | 2015-06-30 | 2019-11-18 | Thromboxane receptor antagonists in AERD/asthma |
US17/705,557 Abandoned US20220218672A1 (en) | 2015-06-30 | 2022-03-28 | Thromboxane Receptor Antagonists in AERD/Asthma |
Country Status (12)
Country | Link |
---|---|
US (4) | US20170000771A1 (en) |
EP (1) | EP3316882A4 (en) |
JP (1) | JP7033454B2 (en) |
KR (2) | KR20220137141A (en) |
CN (2) | CN114569608A (en) |
AU (1) | AU2016285566A1 (en) |
BR (1) | BR112017027298A2 (en) |
CA (1) | CA2990880A1 (en) |
HK (1) | HK1250916A1 (en) |
MX (1) | MX2017017155A (en) |
WO (1) | WO2017004040A1 (en) |
ZA (1) | ZA201708163B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9693998B2 (en) | 2014-05-16 | 2017-07-04 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
US10064845B2 (en) | 2016-05-11 | 2018-09-04 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090012136A1 (en) * | 2007-05-03 | 2009-01-08 | Portola Pharmaceuticals, Inc. | Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2809377A1 (en) | 1978-03-04 | 1979-09-13 | Boehringer Mannheim Gmbh | PHENOXYALKYL CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
DE3000377A1 (en) | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | NEW SULPHONAMIDES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
US4537981A (en) | 1981-11-09 | 1985-08-27 | E. R. Squibb & Sons, Inc. | 7-Oxabicycloheptane and 7-oxabicycloheptene compounds |
US4416896A (en) | 1982-05-17 | 1983-11-22 | E. R. Squibb & Sons, Inc. | 7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease |
US4663336A (en) | 1985-07-01 | 1987-05-05 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease |
US4752616A (en) | 1987-06-29 | 1988-06-21 | E. R. Squibb & Sons, Inc. | Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use |
US5066480A (en) | 1988-04-11 | 1991-11-19 | E. R. Squibb & Sons, Inc. | Method of preventing or reducing adverse reactions to protamine using a thromboxane a2 receptor antagonist |
US4839384A (en) | 1988-10-07 | 1989-06-13 | E. R. Squibb & Sons, Inc. | Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist |
US5100889A (en) | 1989-04-03 | 1992-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
JPH02273625A (en) | 1989-04-14 | 1990-11-08 | Takeda Chem Ind Ltd | Preventive or treating agent for hyperendoserine |
US4977174A (en) | 1989-06-12 | 1990-12-11 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
US5128359A (en) | 1990-02-16 | 1992-07-07 | Laboratoires Upsa | Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation |
ZA911453B (en) | 1990-03-19 | 1991-11-27 | Squibb & Sons Inc | Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation |
US5399725A (en) | 1993-05-27 | 1995-03-21 | Bristol-Myers Squibb Co. | 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same |
IL110376A (en) | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof |
US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
US6509348B1 (en) | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
US20030040534A1 (en) | 2001-04-16 | 2003-02-27 | Hughes David E. | Enantiomers of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide |
WO2006002073A2 (en) | 2004-06-15 | 2006-01-05 | Vanderbilt University | Method for preventing heme-induced lipid peroxidation |
DE102005001795A1 (en) * | 2004-10-07 | 2006-04-13 | Symrise Gmbh & Co. Kg | Papierrollenhalter |
US7358091B2 (en) | 2004-12-14 | 2008-04-15 | Portola Pharmaceuticals, Inc. | Device and methods for identifying and treating aspirin non-responsive patients |
UA86528C2 (en) | 2005-06-10 | 2009-04-27 | Донг-А Фармацевтікал.Ко., Лтд. | composition for prevention and treatment of liver diseases containing pyrazolopyrimidine derivative |
WO2008128038A2 (en) | 2007-04-13 | 2008-10-23 | The Scripps Research Institute | Methods and compositions for treating cardiac dysfunctions |
US8299097B2 (en) | 2008-09-12 | 2012-10-30 | The Brigham And Women's Hospital, Inc. | Methods for treating inflammatory disorders |
AU2011279144A1 (en) * | 2010-07-14 | 2013-01-24 | Cumberland Emerging Technologies, Inc | Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists |
CN103987697B (en) | 2011-10-14 | 2017-04-26 | 百时美施贵宝公司 | Substituted tetrahydroisoquinoline compounds as factor XIA inhibitors |
WO2014039223A1 (en) * | 2012-09-07 | 2014-03-13 | The Brigham And Women's Hospital, Inc. | Diagnosis and treatment of aspirin-exacerbated respiratory disease (aerd) |
US9693998B2 (en) | 2014-05-16 | 2017-07-04 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
EP3448309A4 (en) | 2016-04-27 | 2020-01-15 | Cumberland Pharmaceuticals Inc. | Ifetroban treatment for systemic sclerosis |
US10064845B2 (en) | 2016-05-11 | 2018-09-04 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists |
US20180050020A1 (en) | 2016-08-22 | 2018-02-22 | Cumberland Pharmaceuticals, Inc. | Ifetroban treatment of portal hypertension |
-
2016
- 2016-06-28 CA CA2990880A patent/CA2990880A1/en not_active Abandoned
- 2016-06-28 MX MX2017017155A patent/MX2017017155A/en unknown
- 2016-06-28 KR KR1020227033154A patent/KR20220137141A/en not_active Application Discontinuation
- 2016-06-28 JP JP2017567813A patent/JP7033454B2/en active Active
- 2016-06-28 CN CN202210244047.7A patent/CN114569608A/en active Pending
- 2016-06-28 KR KR1020187002702A patent/KR102448406B1/en active IP Right Grant
- 2016-06-28 WO PCT/US2016/039816 patent/WO2017004040A1/en active Application Filing
- 2016-06-28 EP EP16818596.5A patent/EP3316882A4/en not_active Withdrawn
- 2016-06-28 CN CN201680037498.6A patent/CN107708692A/en active Pending
- 2016-06-28 AU AU2016285566A patent/AU2016285566A1/en not_active Abandoned
- 2016-06-28 US US15/195,265 patent/US20170000771A1/en not_active Abandoned
- 2016-06-28 BR BR112017027298-9A patent/BR112017027298A2/en not_active IP Right Cessation
-
2017
- 2017-11-30 ZA ZA2017/08163A patent/ZA201708163B/en unknown
-
2018
- 2018-08-10 HK HK18110290.6A patent/HK1250916A1/en unknown
-
2019
- 2019-11-18 US US16/687,151 patent/US11571412B2/en active Active
-
2022
- 2022-03-28 US US17/705,557 patent/US20220218672A1/en not_active Abandoned
- 2022-03-28 US US17/705,522 patent/US20220211674A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090012136A1 (en) * | 2007-05-03 | 2009-01-08 | Portola Pharmaceuticals, Inc. | Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists |
Non-Patent Citations (1)
Title |
---|
ClinicalTrials.gov; "Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease"; First Posted: 2014 Aug 13; ClinicalTrials.gov Identifier: NCT02216357 (Year: 2014) * |
Also Published As
Publication number | Publication date |
---|---|
JP7033454B2 (en) | 2022-03-10 |
US20200155513A1 (en) | 2020-05-21 |
KR102448406B1 (en) | 2022-09-27 |
WO2017004040A1 (en) | 2017-01-05 |
EP3316882A4 (en) | 2019-02-20 |
BR112017027298A2 (en) | 2018-09-04 |
KR20180037951A (en) | 2018-04-13 |
ZA201708163B (en) | 2018-11-28 |
US20220218672A1 (en) | 2022-07-14 |
AU2016285566A1 (en) | 2017-12-14 |
EP3316882A1 (en) | 2018-05-09 |
US11571412B2 (en) | 2023-02-07 |
KR20220137141A (en) | 2022-10-11 |
HK1250916A1 (en) | 2019-01-18 |
CN107708692A (en) | 2018-02-16 |
CN114569608A (en) | 2022-06-03 |
MX2017017155A (en) | 2018-08-09 |
JP2018519315A (en) | 2018-07-19 |
CA2990880A1 (en) | 2017-01-05 |
US20170000771A1 (en) | 2017-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220211674A1 (en) | Thromboxane Receptor Antagonists in AERD/Asthma | |
US10925860B2 (en) | Compositions and methods of treating cardiac fibrosis with ifetroban | |
US20200171007A1 (en) | Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists | |
US20200101067A1 (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
AU2014249534B2 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
JP2005508346A (en) | Combinations for the treatment of immune inflammatory diseases | |
US20190151291A1 (en) | Ifetroban treatment of portal hypertension | |
CN115624549A (en) | Compositions and methods for treating muscular dystrophy using thromboxane-A2 receptor antagonists | |
AU2017219121A1 (en) | Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists | |
US20230129262A1 (en) | Methods and pharmaceutical compositions of thromboxane a2 receptor antagonist for the treatment of covid-19 | |
US20230270726A1 (en) | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | |
JPH09511988A (en) | How to treat allergic rhinitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CUMBERLAND PHARMACEUTICALS INC., TENNESSEE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PAVLIV, LEO;REEL/FRAME:059410/0182 Effective date: 20160627 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |